CURRICULUM VITAE
advertisement
1 CURRICULUM VITAE Name Mark Gabriel Lebwohl Telephone 212.241.9728 Education: 1974 BA, Columbia College (summa cum laude) 1978 MD, Harvard Medical School Training 1978-1979 Internship in Internal Medicine Mount Sinai Hospital, New York, NY 1979-1981 Residency in Internal Medicine Mount Sinai Hospital, New York, NY 1981-1983 Residency in Dermatology Mount Sinai Hospital, New York, NY Academic Appointments: 1983-1988 Assistant Professor of Dermatology Mount Sinai School of Medicine, New York, NY 1988-1992 Associate Professor of Dermatology Mount Sinai School of Medicine, New York, NY 1993- Professor of Dermatology Mount Sinai School of Medicine, New York, NY Hospital Appointments: 1982- Director, Phototherapy Unit Mount Sinai Hospital, New York, NY 1983- Clinical Director, Department of Dermatology Mount Sinai Hospital, New York, NY 1988 Director, Division of Clinical Dermatology Mount Sinai School of Medicine, New York, NY 1989-1995 Vice Chairman, Department of Dermatology Mount Sinai School of Medicine, New York, NY 2 1986-1987 1991-1992 1995-1996 Acting chairman, Department of Dermatology Mount Sinai School of Medicine, New York, NY 1996- Chairman, Department of Dermatology Mount Sinai School of Medicine, New York, NY Certification: 1981-1983 American Board of Internal Medicine 1982 American Board of Dermatolgoy Licensure 1981-1984 New York State #141913 Honors: 1970, 1971 1972, 1973 Dean’s List, Columbia College 1974 King’s Crown Activities Award Columbia College 1974 Phi Beta Kappa 1978-1979 X-ray award of the Department of Radiology Mount Sinai School of Medicine, New York, NY First Prize 1983 Residents’ Night, Dermatology Section The New York Academy of Medicine Award for presentation on Pseudoxanthoma Elasticum 1988 Henry Perlman Lecture Thomas Jefferson Medical College 1989 Featured Speaker, Annual Meeting of the National Psoriasis Foundation 1989 Featured Speaker, Annual Meeting of the Illinois Dermatological Society 1991 Featured Speaker, Annual Summer Meeting Massachusetts Academy of Dermatology 3 1992 Featured Speaker European Psoriasis Symposium 1993 Featured Speaker, Turkish Dermatology Symposium 1993 Howard Fox Lecturer New York University Medical Center 1991 Founder’s Award National Psoriasis Foundation 1993 Featured Speaker, New Mexico Dermatological Society 1994 Featured Speaker, Dermatology Section of The Philadelphia College of Physicians 1994 Wiley Sams Lecture Florida Dermatological Society 1994 Featured Speaker, Deer Valley Psoriasis Symposium, National Psoriasis Foundation 1994 Featured Speaker, New Jersey Dermatological Society 1995 Featured Speaker, International Gulf Council Conference 1995 Ralph Grover Lecture Long Island Dermatological Society 1998 Ralph Grover Lecture Long Island Dermatological Society 1999 Donald and Margaret Ruch Lecture University of Rochester School of Medicine S. Robert Narins Lecturer University of Buffalo 2000 2000 Teaching Award American Osteopathic College of Dermatology 2000 PXE International Award 2000 PXE International Honoree 4 2002 Presidential Citation American Academy of Dermatology For exceptional leadership and vision in advancing the American Academy of Dermatology in the specialty of dermatology and in improving our ability to deliver quality dermatogic care to our patients. 2002 John W. Weiss, MD Lectureship San Francisco Dermatological Society 2000 The Jacobi Medallion The Mount Sinai Alumni Award for Distinguished Achievement in the field of Medicine. 2003 Man of the Year Award Awarded by Faculty and Staff Department of Dermatology The Mount Sinai Medical Center 2003 British Medical Association Medical Books Competition Highly commended electronic media award presented to Mark G. Lebwohl, M.D. for Treatment of Skin Disease, PDA version. 2005 Presidential Citation for Excellence American Osteopathic College of Dermatology 2005 Program Committee, Distinguished Service Award American Dermatological Association 2006 Presidential Citation American Academy of Dermatology For service to the Academy on psoriasis and with the Psoriasis Foundation 2006 Honorary Chairman 1st World Psoriasis and Psoriatic Arthritis Conference May 31 – June 4, 2006, Stockholm, Sweden. International Federation of Psoriasis Associations and its patron, His Majesty King Carl Gustav of Sweden. 2006 Winner, The Society of Authors and the Royal Society of Medicine Book Awards for New Edition of an Edited Book Treatment of Skin Disease: Comprehensive Therapeutic Strategies (2nd edition) Mark G. Lebwohl, John Berth-Jones, Ian Coulson and Warren R. Heymann (Mosby) 2006 Sam Moschella Lectureship, New England Dermatologic Society 5 2007 American Academy of Dermatology Bronze Award, Leadership Circle for Volunteerism 2009 Columbia College Dean’s Award 2010 National Psoriasis Foundation 2009 Volunteer of the Year 2010 President’s Council on Service and Civic Participation President’s Volunteer Service Award 2010 The Sid Barsky Visiting Professor Chicago Dermatological Society 2010 Best teacher and Mentor of the Millennium Presented by the Dermatology Residents The Mount Sinai Hosptial 2010 R. K. Schachter Lecturer University of Toronto 2010 Richard Belcher Lectureship Ohio Dermatologic Association 2010 Honorary Corresponding Member Pacific Dermatologic Assocation 2010 Inaugural Lecturer for Clinical Dermatology Lectureship, Sponsored by the Clinical Faculty Yale University November 17, 2010 Visiting Professorships: 1986 Downstate Medical College 1988 Thomas Jefferson University, Jefferson Medical College 1989 State University of New York at Downstate Medical College 1990 New York Medical College 1991 Albert Einstein College of Medicine 1992 Rutgers University School of Medicine 1993 University of New Mexico 6 1994 University of Connecticut Health Center School of Medicine 1994 Downstate Medical Center 1994 University of Maryland, School of Medicine 1994 University of Louisville 1994 Harvard Medical School 1995 Cook County Medical Center 1995 Ochsner Clinic 1995 Thomas Jefferson University Jefferson Medical College 1995 Cleveland Clinic 1995 Brown University 1996 University of California School of Medicine, San Francisco 1996 New Jersey Medical School Robert Wood Johnson School of Medicine 1996 University of Florida at Gainesville 1996 Bowman Gray School of Medicine 1996 Wilford Hall and Brooke Army Medical Center 1996 Wayne State 1996 University of California at San Francisco 1997 Geisinger Medical Center 1997 University of Pennsylvania 1997 Columbia-Presbyterian Medical Center 1998 Downstate Medical Center 1998 Cornell University Medical College 1999 Henry Ford Hospital 2000 Harvard Medical School 7 2000 Columbia College of Physicians & Surgeons 2000 New Jersey Medical College 2000 Albert Einstein College of Medicine 2001 University of South Florida College of Medicine 2010 Yale University Memberships in Professional Organizations: 1983- Fellow, American Academy of Dermatology 1983- New York County Medical Society 1983-1985 American Physicians Fellowship 1983-1985 Society for Investigative Dermatology 1983 Dermatologic Society of Greater New York 1983- American Medical Association 1984- Manhattan Dermatological Society 1986- International Dermatologic Society 1987- Fellow of the American College of Physicians 1988- Dermatology Foundation 1988- New York State Dermatologic Society 1991- New York Dermatologic Society 1992- New York Academy of Medicine, Dermatology Section 1995- Association of Professors of Dermatology 1996- American Contact Dermatitis Society 1996- Noah Worcester Dermatologic Society 1996- American Society for Dermatologic Surgery 1996- Council for Nail Disorders 8 2008- Fellow, American Society for Dermatologic Surgery Offices in Medical Organizations: 1985-1986 Past President, Manhattan Dermatologic Society 1996 Chairman, Dermatology Section The New York Academy of Medicine 1999-2000 Secretary/Treasurer Medical Dermatology Society 2000-2001 President New York State Society of Dermatology Professional Organizations – Offices & Activities: Appointed Positions 1985 Faculty, Genodermatoses Symposium American Academy of Dermatology 1985-1995 American Academy of Dermatology, Skin Cancer Campaign Coordinator for New York State 1987- Medical Advisory Committee, American Social Health Association, New York HELP Chapter 1988- Medical Advisory Committee, National Association for Pseudoxanthoma Elasticum 1990-1991 National Board of Podiatric Medical Examiners, Dermatology Test Committee 1990-1996 Medical Advisory Board, National Psoriasis Foundation 1992-1995 Vice Chairman, Leaders’ Society New York State 1993, 1994, 1996 Faculty, Psoriasis Symposium American Academy of Dermatology 1992 Faculty, Itch Symposium American Academy of Dermatology 1993-1998 Director, Diagnostic Update Symposium American Academy of Dermatology 9 1994-1996 Committee on Preventive Medicine Medical Society of the State of New York 1995-1999 Health Industry Liaison Committee American Academy of Dermatology 1994 Faculty, General Session, Academy ’95 American Academy of Dermatology 1996-1999 Chairman, Health Industry Liaison Committee American Academy of Dermatology 1994 Faculty, Recertification Course American Academy of Dermatology 1996 Director, General Session, Academy ’96 American Academy of Dermatology 1996-2000 Member, Psoriasis Task Force American Academy of Dermatology 1997-1999 Member, Communication Council American Academy of Dermatology 1996- Member, Executive Committee The Dermatologic Society of Greater New York 1997-2000 Member, Dermatology Manpower Committee The Dermatologic Society of Greater New York 1997-2000 Member, Program Committee The Dermatologic Society of Greater New York 1997 Chairman, Scientific Sessions 75th Atlantic Dermatological Conference (May) New York, NY 1998 Co-chairman, American Academy of Dermatology, Study Group, Academy Efforts/Industry Relationships for the Program for Dermatology for the 21st Century 1997 Member, Practice Environment: Workforce Study Group Program for Dermatology for the 21st Century American Academy of Dermatology 1999-2004 Scientific Assembly Committee, American Academy of Dermatology 10 1999-2006 Medical Advisory Board, National Psoriasis Foundation 1997 Scientific Advisory Board, 2nd Joint Meeting International Psoriasis Symposium and European Congress on Psoriasis (June) 1997 Chair, October 11th Session of the 6th International GCC Dermatology & Venereology Conference & Exhibition 1997 National Advisory Group on Actinic Keratoses American Academy of Dermatology 2003 Member, Guidelines/Outcomes Task Force American Academy of Dermatology 2003-2004 Chairman, Scientific Assembly Committee American Academy of Dermatology 2003 Faculty Member, Consensus Panel on the Benefit/Risk Profile on TNF Blocking Agents 2003-2005 American Academy of Dermatology, Council on Communications Work Group for PsoriasisNet. www.skincarephysicians.com 2005 Reviewer, NIAMS Multi-disciplinary Research Applications Study Section 2006-2011 American Academy of Dermatology Annual Meeting Evaluation Task Force 2006 Member, Corporate Development Committee Dermatology Foundation 2002-2008 Medical Board, Chairman National Psoriasis Foundation 2009- Medical Board, Reappointed as Chairman National Psoriasis Foundation 2010- Founding Member and Advisory Board Member International Society for Genetic Dermatology Elected Positions 1985-1986 President, Manhattan Dermatological Society 11 1986-1999 National Advisory Council American Academy of Dermatology 1991-1997 Board of Directors New York State Dermatologic Society 1993 Secretary/Treasurer, Dermatology Section The New York Academy of Medicine 1994 President, Dermatology Section The New York Academy of Medicine 2000-2003 President, New York State Society of Dermatology 2003-2004 President, New York Dermatological Society 2005-2009 Program Committee, Member American Dermatological Association, Inc. 2011-2015 Board of Directors, Member American Academy of Dermatology Service to Professional Publications: 1989 Founding Editor, Psoriasis Forum 1989 Assistant Editor The Mount Sinai Journal of Medicine 1989 Editorial Board, The Bulletin 1990 Consulting Editor, Problems in Dermatologic Diagnosis and Management Volume II American Academy of Dermatology 1993- Editor, The Bulletin National Psoriasis Foundation 1993 Editorial Board, NAPE Bulletin National Association for Pseudoxanthoma Elasticum 1993-1998 Editorial Board, Journal of the American Academy of Dermatology 1995- Editor-in-Chief, Psoriasis Forum National Psoriasis Foundation 1995- Editorial Board, Clinics in Dermatology 12 1984-1987, 1991 Reviewer, U.S. Pharmacopia 1985 Reviewer, Chest, the Cardiopulmonary Journal 1987-1989, 1991-1996 Reviewer, Journal of the American Academy of Dermatology 1987-1989, 1991-1992 1994, 1995 Reviewer, the Journal of Investigative Dermatology 1989, 1992-1994, 1996, 1999, 2002 Reviewer, Archives of Internal Medicine 1990 Reviewer, Environmental Research 1991-1996, 1998 Reviewer, American Journal of Industrial Medicine 1992, 1994-1999 Reviewer, Archives of Dermatology 1994 Reviewer, Journal of Clinical Investigation 1995, 1996, 2000 Reviewer, Pediatric Dermatology 1996-1999 2007 Reviewer, The Lancet 1997 Reviewer, Journal of Dermatological Treatment 1998-2007 Assistant Editor, Journal of the American Academy of Dermatology 1998-2007 Medical Pearl Editor, Journal of the American Academy of Dermatology 1999- Member, Editorial Advisory Board Skin Therapy Letter 1999 Reviewer, Clinical Therapeutics 1999 Editor, emedicine online textbooks, Dermatology, wjames@emedicine. Com 2000 International Editorial Board Dermatology in Clinical Practice 2000 International Editorial Board 13 American Journal of Clinical Dermatology 2000 Reviewer, New England Journal of Medicine 2000 Editorial Board, Journal of Cutaneous Medicine and Surgery 2000… Reviewer, Journal of Cutaneous Medicine and Surgery 2000- 2004 2000-2004 2004-2008, 2010 2004-2008, 2010 2010 Editorial Board, WebMD Scientific American Medicine Editor, Dermatology Section, Scientific American Medicine Editorial Board, ACP Medicine Editor, Dermatology Section, ACP Medicine. Editorial Board, Dermatologic Surgery 2001 Reviewer, Vaccine 2001 Editorial Board The Gulf Journal of Dermatology & Venereology 2001 Reviewer, British Journal of Dermatology 2001 Reviewer, Experimental Dermatology 2001-2002 Editor, New York Dermatologist 2001 Reviewer, Nature Magazine 2001 Editorial Board, Journal of the European Academy of Dermatology and Venereology 2003 Editorial Advisory Board, Contemporary Dermatology 2001 Reviewer, MUIR 2001 International Editorial Board, British Journal of Dermatology 2001 Reviewer, The Lancet 2001 Advisory Board, Der Hautarzt 2001 Editorial Advisory Board The Journal of Aesthetic and Clinical Dermatology 2001 Editorial Board, Journal of Skin Cancer 2001 Editorial Board, Latin American Journal of Psoriasis and Psoriatic Arthritis 14 2005 Editorial Advisory Panel, Expert Review of Dermatology 2008 Editorial Board, Clinical and Aesthetic Dermatology 2008 Editorial Review Committee Journal of the American Osteopathic College of Dermatology 2008 Advisory Board, Dermatology F1000 Medicine Reports 2008 Reviewer, New England Journal of Medicine 2008-2013 Editorial Board, Journal of the American Academy of Dermatology 2009-2013 Member, International Editorial Board Journal of Drugs in Dermatology 2009- Board of Contributing Editors Derm101 2010-2014 Associate Editor, International Editorial Board Journal of Drugs in Dermatology 2010- Editorial Board, Yearbook of Dermatology and Dermatologic Surgery Other Professional Service: 1985-1993 Director, Skin Cancer Screening Clinic Mount Sinai Hospital 1986 Chairman, PXE Symposium The Mount Sinai School of Medicine 1987 Columbia College Alumni Secondary Schools Committee 1988-1993 Executive Committee, Campaign for the Third Century of Harvard Medicine 1987- Director, Dermatology Course New York College of Podiatric Medicine 1988 National Psoriasis Foundation Audio Cassette “Psoriatic Arthritis” 1988 Chairman, Psoriasis Symposium, Annual Meeting of 15 The Society for Investigative Dermatology, Seattle, WA 1991-1995 American Board of Dermatology Question Contributor 1992- American Board of Internal Medicine Question Contributor 1991 Chairman, Phototherapy Symposium The Mount Sinai School of Medicine, New York, NY 1992 Cochairman, International Symposium on Pseudoxanthoma Elasticum, Philadelphia, PA 1992 Cochairman, European Symposium on Psoriasis and Topical Steroids Munich, Germany 1991 Chairman, Psoriasis Symposium Istanbul, Turkey 1993 Chairman, Psoriasis Symposium Ankara, Turkey 1993 Chairman, Psoriasis Symposium Adana, Turkey 1993 Chairman, Psoriasis Symposium New Orleans, LA 1994 Program Chairman, New York Metropolitan Area Symposium, Herpes Viruses: Recent Developments and New Treatments, New York, NY 1995 Chairman, Psoriasis Symposium, The Mount Sinai School of Medicine, New York, NY 1996 Cochairman, Scientific Committee Atlantic Dermatology Conference, New York, NY 1996 Chairman, First North American Calcipotriene/Calcipotriol Symposium, Vancouver, Canada 1996 Director, Therapeutics Symposium, Summer Meeting, Orlando, FL American Academy of Dermatology 1996- National Faculty, The Core Content Review of Family Medicine 1997 Chairman, Round Table Meeting on Salicylic Acid in Dermatology, New York, NY 1997 Chairman, Pharmacology/Clinical Trials Symposium, (July) Society for Investigative Dermatology, New York, NY 1997 Chairman, New Horizons in the Management of Psoriasis, Summer Meeting, (July) American Academy of Dermatology, New York, NY 16 1997 Chairman, Patient Presentations, Summer Meeting (August) American Academy of Dermatology, New York, NY 1997 Chairman, General Session on Therapeutics, Summer Meeting (August) American Academy of Dermatology, New York, NY 1997 Chairman, Patient Presentations, Summer Meeting (August) American Academy of Dermatology, New York, NY 1997- Program Committee, Dermatological Society of Greater New York 1997- Executive Committee, Dermatological Society of Greater New York 1997 Chairman, Session on Clinical Updates Organizer of International Centennial PXE Meeting; 1998 FDA Consultant, Committee on Ophthalmic and Dermatologic Drugs 1998 Director, Therapeutic Symposium Summer Meeting (August) American Academy of Dermatology 1999 Director of the Symposium, Therapeutic Advances in Dermatology, Summer Meeting (July) American Academy of Dermatology 1998-2002 Chairman, Psoriasis Symposium, American Academy of Dermatology 1999-2003 Chairman, Psoriasis Task Force, American Academy of Dermatology 1998-2003 Chairman, Fall Clinical Conference in Dermatology 1999 Contributor, USPDI, Drug Information for the Health Care Professional 1999 Member, Developmental Initiatives Task Force, American Academy of Dermatology 1999 Co-course Director, Advances in Medical and Surgical Dermatology for the New Millennium, Department of Dermatology, The Mount Sinai Medical School 2003- Minority Medical Student Mentor Program American Academy of Dermatology Association 2007-2008 Dermatology Foundation, Trustee-at-Large 2008 Live4Life Foundation Medical Advisory Board Hospital and Medical School Committees: 17 1983- Executive Committee, Department of Dermatology 1983-1988 Chairman, Dermatology Residency Selection Committee 1983-1988 Faculty Practice Assembly 1984 Quality Assurance Review Committee 1984-1988 Library Committee 1987 Ad Hoc Advisory Committee on the Future Direction of the Faculty Practice Associates 1987 Humanities and Medicine Program 1987 Compensation Subcommittee, Advisory Committee on the Future Direction of the Faculty Practice Associates 1987 Search Committee for Pathology Chairman 1987- Faculty Practice Benefits Committee 1988-1990 Faculty Practice Executive Council 1989-1993 Faculty Practice Space Committee Co-Chairman 1989-1990 Faculty Council, Alternate 1989-1990 Faculty Council Services Committee 1990 Vice Chairman, Faculty Practice Committee on Teaching and Research 1991 Search Committee for Internal Medicine Chairman 1992-1993 Search Committee for Internal Medicine Chairman 1993- Committee on Appointments and Promotions, Alternate 1996 Board of Governors, Faculty Practice 2002-2003 Finance Committee Publications: Books and Atlases 1. Lebwohl M. (1988). Difficult Diagnoses in Dermatology. New York: Churchill Livingston. 18 2. Lebwohl M. (1995).Atlas of the Skin and Systemic Disease (1995). New York: Churchill Livingstone. 3. Lebwohl, M., & Zanolli, M. (1995) Psoriasis. In Dermatologic Clinics of North America. Philadelphia, PA: W. B. Saunders. 4. Lebwohl, M, Heymann, WR, Berth-Jones, J & Coulson, I. (Eds.). (2002). Treatment of Skin Disease: Comprehensive Therapeutic Strategies. London: Mosby. 5. Lebwohl, M, Heymann, WR, Berth-Jones, J & Coulson, I. (Eds.). (2004). Tratamentode Doencas da Pele. Portuguese translation of Treatment of Skin Disease: Comprehensive Therapeutic Strategies. Basil: Manole. 6. Lebwohl, MG. (2004). The Skin and Systemic Disease: A Color Atlas and Text. 2nd edition. New York: Churchill Livingstone. 7. Lebwohl, MG. (2004). Peau et Maladies Systemiques. French translation of The Skin and Systemic Disease: A Color Atlas and Text, 2nd edition, Paris: Elsevier. 8. Lebwohl, M, Heymann, WR, Berth-Jones, J & Coulson, I. (Eds.). (2006). Treatment of Skin Disease: Comprehensive Therapeutic Strategies. London: Mosby. 9. Lebwohl, M, Heymann, WR, Berth-Jones, J & Coulson, I. (Eds.). (2006). Leczenie chorób skóry Redakcja wydania I polskiego. Polish translation of Treatment of Skin Disease: Comprehensive Therapeutic Strategies. London: Mosby. 10. Koo, JM, Lebwohl, MG, Lee, CS. (Eds.). (2006). Mild-to-Moderate Psoriasis. New York: Informa Healthcare. 11. Koo, JM, Lebwohl, MG, Lee, CS. (Eds.). (2008). Mild-to-Moderate Psoriasis. New York: Informa Healthcare. 12. Koo, JM, Lebwohl, MG, Lee, CS. (Eds.). (2009). Moderate-to-Severe Psoriasis. New York: Informa Healthcare. 13. Lebwohl, M, Heymann, WR, Berth-Jones, J & Coulson, I. (Eds.). (2010). Treatment of Skin Disease: Comprehensive Therapeutic Strategies. London: Mosby. Original Peer-Reviewed Reports 1. Poliak SC, Lebwohl MG, Parris A, Prioleau PG: Reactive perforating collagenosis associated with diabetes mellitus. N Engl J Med 1982;306(2):81-2. 2. Lebwohl M, Distefano D, Prioleau PG, Uram M, Yannuzzi LA, Fleischmajer R: Pseudoxanthoma elasticum and mitral valve prolapse. New Engl J Med 1982;307(4):228-31. 3. Lebwohl M, Fleischmajer R, Janowitz H, Present D, Prioleau PG: Metastatic Crohn’s disease. J Am Acad Dermatol 1984;10(1):33-8. 4. Fleischmajer R, Timpl R, Dziadek M, Lebwohl M: Basement membrane proteins, interstitial collagens, and fibronectin in neurofibroma. J Invest Dermatol 1985;85(1):54-9. 19 5. Lebwohl M, Berman B, France DS: Addition of short contact anthralin therapy to an ultraviolet B phototherapy regimen: assessment of efficacy. J Am Acad Dermatol 1985;13(5 Pt 1):780-4. 6. Sonnenfeld KH, Bernd P, Sobue G, Lebwohl M, Rubenstein AE: Nerve growth factor receptors on dissociated neurofibroma Schwann-like cells. Cancer Res 1986;46(3):1446-52. 7. Beitler M, Eng A, Kilgour M, Lebwohl M: Association between acrochordons and colonic polyps. J Am Acad Dermatol 1986;14(6):1042-44. 8. Longas MO, Wisch P, Lebwohl M, Fleischmajer R. Glycosaminoglycans of skin and urine in pseudoxanthoma elasticum: evidence for chondroitin 6-sulfate alteration. Clin Chim Acta 1986;155(3):227-36. 9. Rigel DS, Friedman RJ, Kopf AW, Weltman R, Prioleau PG, Safai B, Lebwohl M, Eliezri Y, Torre DP, Binford RT Jr, Cipollaro VA, Biro L, Charbonneau D, Mosettis A: Importance of complete cutaneous examination for the detection of malignant melanoma. J Am Acad Dermatol 1986;14(5 Pt 1):857-60. 10. Berman B, Davis-Reed L, Silverstein L, Jaliman D, France D, Lebwohl M: Treatment of verrucae vulgaris with alpha2 interferon. J Infect Dis 1986;154(2):328-30. 11. Lemlich G, Schwam L, Lebwohl M: Kaposi’s sarcoma and acquired immunodeficiency syndrome: Postmortem findings in twenty-four cases. J Am Acad Dermatol 1987;16(2 Pt 1):319- 25. 12. Freed JA, Pervez NK, Chen V, Lebwohl M, Damsker B. Cutaneous mycobacteriosis: occurrence and significnce in two patients with the acquired immunodeficiency syndrome. Arch Dermatol 1987;123(12):1601-3. 13. Lebwohl M, Phelps RG, Yannuzzi LA, Chang S, Schwartz I, Fuchs W: Diagnosis of pseudoxanthoma elasticum by scar biopsy in patients without characteristic skin lesions. N Engl J Med 1987; 317(6):347-50. 14. Norwood-Galloway A, Lebwohl M, Phelps RG, Raucher H: Subcutaneous fat necrosis of the newborn with hypercalcemia. J Am Acad Dermatol 1987;16(2 Pt 2):435-39. 15. Barax CN, Lebwohl M, Phelps RG: Multiple hamartoma syndrome. J Am Acad Dermatol 1987;17(2 Pt 2):342-6. 16. Peltonen J, Jaakkola S, Lebwohl M, Renvall S, Risteli L Virtanen I, Uitto J: Cellular differentiation and expression of matrix genes in type I neurofibromatosis: Lab Invest 1988;59(6):760-71. 17. Schwartz E, Cruickshank FA, Lebwohl M: Elastase-like protease and elastolytic activities expressed in cultured dermal fibroblasts derived from lesional skin of patients with pseudoxanthoma elasticum, actinic elastosis, and cutis laxa. Clin Chimca Acta 1988;176(2): 20 219-24. 18. Fishman S, Phelps RG, Lebwohl M, Lieber C: Immunofluorescence and electron microscopic findings in a congenital arrector pilli hamartoma. Am J Dermatopathol 1989;11(4):369-74. 19. London RD, Lebwohl M: Acquired ichthyosis and hyperparathyroidism. J Am Acad Dermatol 1989;21(4 Pt 1):801-2. 20. Groisser D, Bottone EJ, Lebwohl M: Association of Pityrosporum orbiculare (Malassezia furfur) with seborrheic dermatitis in patients with acquired immunodeficiency syndrome (AIDS). J Am Acad Dermatol 1989;20(5 Pt 1):770-3. 21. Schwartz E, Cruickshank FA, Lebwohl M: Determination of desmosines in elastin-related skin disorders by isocratic high-performance liquid chromatography. Exp Mol Pathol 1990;52(1): 63-8. 22. Lebwohl M, Phelps R, Gordon M, Fleischmajer R: Diseases of the dermis J Am Acad Dermatol 1990;23(2 Pt 1):295-9. 23. Lebwohl M, Contard P: Interferon in the treatment of condylomata acuminata. Int J Dermatol 1990;29(10):699-705. 24. Gordon ML, Lebwohl MG, Phelps RG, Cohen SR, Fleischmajer R: Eosinophilic fasciitis associated with tryptophan ingestion. A manifestation of eosinophioia-myalgia syndrome. Arch Dermatol 1991; 127(2):217-20. 25. Olsen EA, Cram DL, Ellis CN, Hickman JG, Jacobson C, Jenkins EE,Lasser AE, Lebwohl M, Leibsohn E, Medansky RS, Oestreicher MI, Savin RC, Scher RK, Shavin JS, Smith RD, Day RM: A double-blind, vehicle- controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis. J Am Acad Dermatol 1991;24(3):443-7. 26. Sollberg S, Muona P, Lebwohl M, Peltonen J, Uitto J: Presence of type I and VI collagen mRNAs in endothelial cells in cutaneous neurofibromas. Lab Invest 1991;65(2):237-42. 27. Dunaif A, Green G, Phelps RG, Lebwohl M, Futterweit W, Lewy L: Acanthosis nigricans, insulin action, and hyperandrogenism: clinical, histological, and biochemical findings. J Clin Endocrinol Metab 1991;73(3):590-5. 28. Schwartz E, Thieberg M, Cruickshank FA, Lebwohl M: Elastase digestion of normal and pseudoxanthoma elasticum lesional skin elastins. Exp Mol Pathol 1991;55(2):190-5. 29. Lebwohl M, Chen V, Conant M, Connor J, Douglas J, Eron L, Trout JR, Plasse T: Recombinant alpha-2 interferon gel treatment of recurrent herpes genitalis. Antiviral Res 1992;17:235-43. 30. Keltz M, Lebwohl M, Bishop S: Peristomal pyoderma gangrenosum. J Am Acad Dermatol 1992;27(2 Pt 2):360-4. 21 31. Davis K, Bottone EJ, Lucas D, Lebwohl M: Sterility of refrigerated injectable collagen syringes after injection of patient. J Am Acad Dermatol 1992; 27(6 Pt 1):959-61. 32. Christiano AM, Lebwohl MG, Boyd CD, Uitto J: Workshop on pseudoxanthoma elasticum: molecular biology and pathology of the elastic fibers. J Invest Dermatol 1992;99(5):660-3. 33. Lebwohl M, Sacks S, Conant M, Connor J, Douglas JM Jr, Eron L, Marlowe S, Mendelson J, Chen V, Gradstreet P, et al: Recombinant alpha-2 interferon gel treatment of recurrent herpes genitalis. Antiviral Res 1992;17(3):235-43. 34. Lemlich G, Green M, Phelps R, Lebwohl M, Don P, Gordon M: Cutaneous reactions to vitamin K1 injection. J Am Acad Dermatol 1993; 28(2 Pt 2):345-7. 35. Lebwohl M: Images in clinical medicine. Pseudoxanthoma elasticum. N Engl J Med 1993;329(17):1240. 36. Lebwohl M, Schwartz E, Lemlich G. Lovelace O, Shaikh-Bahai F, Fleischmajer R: Abnormalities of connective tissue components in lesional and nonlesional tissue of patients with pseudoxanthoma elasticum. Arch Dermatol Res 1993; 285(3):121-6. 37. Yen BC, Kahn H, Schiller AL, Klein MJ, Phelps RG, Lebwohl MG: Multiple hamartoma syndrome with osteosarcoma. Arch Pathol Lab Med 1993;117(12):1252-4. 38. Lebwohl M, Halperin J, Phelps RG: Brief report: Occult pseudoxanthoma elasticum in patients with premature cardiovascular disease. N Engl J Med 1993;329:1237-9. 39. Lebwohl M, Peets E, Chen V: Limited application of mometasone furoate on the face and intertriginous areas: analysis of safety and efficacy. Int J Dermatol 1993;32(11):830-1. 40. Schwartz E, Cruickshank FA, Christensen CC, Perlish JS, Lebwohl M: Collagen alterations in chronically sun-damaged human skin. PhotochemPhotobiol 1993;58(6):841-4. 41. Lebwohl MG, Schwartz E, Jacobs L, Sakai L, Fleischmajer R: Abnormalities of fibrillin in acquired cutis laxa. J Am Acad Dermatol 1994;30(6):950-4. 42. Lebwohl M, Neldner K, Pope FM, De Paepe A, Christiano A, Boyd CD, Uitto J, McKusick V: Classification of pseudoxanthoma elasticum: report of a consensus conference. J Am Acad Dermatol 1994;30(1):103-7. 43. Fryer EJ, Lebwohl M: Pemphigus vulgaris after initiation of psoralen and UVA therapy for psoriasis. J Am Acad Dermatol 1994;30(4):651-3. 44. Menter MA, See JA, Amend WJ, Ellis CN, Krueger GG, Lebwohl M, Morison WL, Prystowsky JH, Roenigk HH Jr, Shupack JL, Silverman AK, Weinstein GD, Yocum DE, Zanolli MD. Proceedings of the Psoriasis Combination and Rotation Therapy Conference. Deer Valley, Utah, Oct. 7-9, 1994. J Am Acad Dermatol 1994;34 (2 Pt 1):315-21. 22 45. Lambroza E, Cohen SR, Phelps R, Lebwohl M, Braverman IM, DiCostanzo D: Hypopigmented variant of mycosis fungoides: demography, histopathology, and treatment of seven cases. J Am Acad Dermatol 1995;32(6):987-93. 46. Lebwohl M, Longas MO, Konstadt J, Korren R, Grabowski GA, Phelps R, Lemlich G, Schwartz E: Hyaluronic acid and dermatan sulfate in nonlesional pseudoxanthoma elasticum skin. Clin Chim Acta 1995; 238(1):101-7. 47. Lebwohl M, Martinez J, Weber P, DeLuca R: Effects of topical preparations on the erythemogenicity of UVB: implications for psoriasis phototherapy. J Am Acad Dermatol 1995;32(2):469-71. 48. Schwartz E, Feinberg E, Lebwohl M, Mariani TJ, Boyd CD: Ultraviolet radiation increases tropoelastin accumulation by a post-transcriptional mechanism in dermal fibroblasts. J Invest Dermatol 1995;105(1):65-9. 49. Lebwohl MG, Medansky RS, Russo CL, Plott RT: The comparative efficacy of sodium sulfacetamide 10%/ sulfur 5% (Sulfacet-R®) lotion and metronidazole 0.75% (MetroGel®) in the treatment of rosacea. J Geriatric Dermatol 1995;3:191-5. 50. Lebwohl M, Able E, Zanolli M, Koo J, Drake L: Topical therapy for psoriasis. Int J Dermatol 1995;34(10):673-84. 51. Lebwohl M: The evolution of vitamin D analogues for the treatment of psoriasis. Arch Dermatol 1995;131(11):1323-24. 52. Lebwohl MG, Medansky RS, Savin RC, Atton AV: Diflorasone diacetate 0.05% cream in an optimized vehicle versus fluocinonide 0.05% cream for the treatment of psoriasis. J Dermatol Treat 1995;6:219-22. 53. Lebwohl M: Future psoriasis therapy. Dermatol Clin 1995;13(4):915-23. 54. Smalls G, Alaie M, Anzilotti M, Lebwohl M: Henoch-Schonlein purpura. Case report and review of the literature. J Am Pod Med Assoc 1995; 85(11):710-2. 55. Ronna T, Lebwohl M: Cimetidine therapy for plantar warts.J Am PodiatrMed Assoc 1995;85:717-8. 56. Medansky RS, Bronson DM, Jacobson C, Lebwohl M, Roth HL: Management of rosacea. J Geriatr Dermatol 1996;4(A):1-8. 57. Lebwohl M: Efficacy and safety of fluticasone propionate ointment, 0.005%, in the treatment of eczema. Cutis 1996;57(2 Suppl):62-8. 58. Green MS, Prystowsky JH, Cohen SR, Cohen JI, Lebwohl MG: Infectious complications of erythrodermic psoriasis. J Am Acad Dermatol 1996; 34(5 Pt 2):911-4. 23 59. Lebwohl M, Roth HL, Tschen E: A three-week, randomized, double-blind, multicenter study comparing the efficacy of diflorasone diacetate cream and dipropionate cream 0.05% for the treatment of moderate to severe eczema. Cutis 1996;57:14-8. 60. Savin R, Lebwohl M, Medansky RS: A two-week, randomized multi-center study comparing the efficacy of diflorasone diacete cream 0.05% in an optimized vehicle and branded fluocinonide cream 0.05% in the treatment of psoriasis. Cutis 1996;57:9-3. 61. Spruance SL and the Valacyclovir HSV Study Group: A large scale placebo-controlled doseranging trial of perioral valacyclovir for episodic treatment of recurrent herpes genitalis Arch Int Med 1996;156(15):1729-35. 62. Zhang X, Rosenstein BS, Wang Y, Lebwohl M, Mitchell DM, Wei H: Induction of 8-oxo-7,8dihydro-2’-deoxyguanosine by ultraviolet radiation in calf thymus DNA and HeLa cells. Photochem Photobiol 1997;65(1):119-24. 63. Lebwohl ML, Siskin SB, Epinette W, Breneman D, Funicella T, Kalb R, Moore J: A multicenter trial of calcipotriene ointment and halobetasol ointment compard with either agent alone for the treatment of psoriasis. J Am Acad Dermatol 1996;35(2 Pt 1):268-9. 64. Yoles A, Phelps R, Lebwohl M: Pseudoxanthoma elasticum and pregnancy. Cutis 1996;58(2):161-4. 65. Pariser DM, Pariser RJ, Breneman D, Lebwohl M, Kalb R, Moore J, Moss H, Parker C, Fiedler V: Calcipotriene ointment applied once a day for psoriasis: a double-blind, multicenter, placebocontrolled study. ArchDermatol 1996;132(12):1527. 66. Zhang X, Rosenstein BS, Wang Y, Lebwohl M, Wei H: Identification of possible reactive oxygen species involved in ultraviolet radiation-induced oxidative DNA damage. Free Radic Biol Med 1997;23(7):980-5. 67. Lebwohl M. New treatments for alopecia areata. Lancet 1997;349(9047):222-3. 68. Freedman AM, Phelps RG, Lebwohl M: Pyoderma gangrenosum associated with anticardiolipin antibodies in a pregnant patient. Int J Dermatol 1997;36(3):205-7. 69. Hecker D, Lebwohl M: Topical calcipotriene in combination with UVB phototherapy for psoriasis. Int J Dermatol 1997;36(4):302-3. 70. Sadeh JS, Rudikoff D, Gordon ML, Bowden J, Goldman BD, Lebwohl M: Pustular and erythrodermic psoriasis complicated by acute respiratory distress syndrome. Arch Derm 1997;133(6):747-50. 71. Lebwohl M, Hecker D, Martinez J, Sapadin A, Patel B: Interactions between calcipotriene and ultraviolet light. J Am Acad Dermatol 1997;37(1):93-5. 24 72. Jorizzo JL, Magee K, Stewart DM, Lebwohl MG, Rajagopalan R, Brown JJ: Clobetasol propionate emollient 0.05 percent: hypothalamic-pituitary-adrenal-axis safety and four-week clinical efficacy results in plaque-type psoriasis. Cutis 1997;60(1):55-60. 73. Lebwohl M: Topical application of calcipotriene and corticosteroids: combination regimens. J Am Acad Dermatol 1997;37(3 Pt 2): S55-8. 74. Sapadin AN, Lebwohl MG, Teich SA, Phelps RG, DiCostanzo D, Cohen SR: Periumbilical pseudoxanthoma elasticum associated with chronic renal failure and angioid streaks – apparent regression with hemodialysis. J Am Acad Dermatol 1998;39(2 Pt 2):338-44. 75. Lucky AW, Henderson TA, Olson WH, Robisch DM, Lebwohl M, Swinyer LJ: Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. J Am Acad Dermatol 1998;37 (5 Pt 1): 746-54, 1997. 76. Lebwohl M, Tan MH: Psoriasis and stress. Lancet 1998;351(9096):82. 77. Hecker MS, Lebwohl MG: Recalcitrant pyoderma gangrenosum: treatment with thalidomide. J Am Acad Dermatol 1998;38(3):490-1. 78. Roenigk HH Jr, Auerbach R, Maibach H, Weinstein G, Lebwohl M. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 1998;38(3):478-85. 79. Lebwohl M, Lebwohl O: Cutaneous manifestations of inflammatory bowel disease. Inflam Bowel Dis 1998;4(2):142-8. 80. Lebwohl MG, Ast Ernest, Callen JP, Cullen SI, Hong SR, Kulp-Shorten CL, Lowe NJ, Phillips TJ, Rosen T, Wolf DI, Quell JM, Sefton J, Lue JC, Gibson JR, Chandraratna RA. Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis. J Am Acad Dermatol 1998;38(5 Pt 1):705-11. 81. Wang Y, Zhang X. Lebwohl M, DeLeo V, Wei H: Inhibition of ultraviolet B (UVB)-induced cfos and c-jun expression in vivo by a tyrosine kinase inhibitor genistein. Carcinogenesis 1998;19(4):649-54. 82. Morison WL, Baughman RD, Day RM, Forbes PD, Hoenigsmann H, Krueger GG, Lebwohl M, Lew R, Naldi L, Parrish JA, Peipkorn M, Stern RS, Weinstein GD, Whitmore SE: Consensus workshop on the toxic effects of long-term PUVA therapy. Arch Dermatol 1998;134(5):595-8. 83. Wei H, Ca Q, Rahn R, Zhang X, Wang Y, Lebwohl M: DNA structural integrity and base composition affect ultraviolet light-induced oxidative DNA damage. Biochemistry 1998;37(18):6485-90. 84. Ling MR, Swinyer LJ, Jarratt MT, Falo L, Monroe EW, Tharp M, Kalivas J, Weinstein GD, Asarch RG, Drake L, Martin AG, Leyden JJ, Cook J, Pariser DM, Pariser R, Thiers BH, Lebwohl MG , Babel D, Stewart DM, Eaglstein WH, Falanga V, Katz HI, Bergfeld WF, Hanifin JM, Young MR, et al. Once-weekly fluconazole (450 mg) for 4, 6, or 9 months of treatment for distal subungual onychomycosis of the toenail. J Am Acad Dermatol 1998;38(6 Pt 2):S95-102. 25 85. Patel B, Siskin S, Krazmien BA, Lebwohl M: Compatibility of calcipotriene with other topical medications. J Am Acad Dermatol 1998;38(6 Pt 1):1010-11. 86. Nichols K, Desai N, Lebwohl M: Effective sunscreen ingredients and cutaneous irritation in patients with rosacea. Cutis 1998;61(6):344-6. 87. Liu Z, Lu Y, Rosenstein B, Lebwohl M, Wei H: Benzo[a]pyrene enhances the formation of 8hydroxy-2’-deoxyguanosine by ultraviolet A radiation in calf thymus DNA and human epidermoid carcinoma cells. Biochemistry 1998;37(28):10307-12. 88. Wei H, Cai Q, Tian L, Lebwohl M: Tamoxifen reduces endogenous and UV light-induced oxidative damage to DNA, lipid and protein in vitro and in vivo. Carcinogenesis 1998;19(6):1013-18. 89. DeLauro TM, Lebwohl M. Dermatologic manifestations of systemic disease. Clin Podiatr Med Surg 1998;15(3):389-409. 90. Sapadin AN, Lebwohl M, Teich S, Phelps RG, DiCostanzo D, Cohen SR: Periumbilical pseudoxanthoma elasticum associated with chronic renal failure and angioid streaks – apparent regression with hemodialysis. J AmAcad Dermatol 1998;39(2 Pt 2):338-44. 91. Gelfand JM, Rudikoff D, Lebwohl M, Klotman ME: Effect of UV-B phototherapy on plasma HIV Type 1 RNA viral level: a self-controlled prospective study. Arch Dermatol 1998;134(8):940-5. 92. Rudikoff D, Lebwohl M: Atopic dermatitis. Lancet 1998;351(9117):1715-21. 93. Lebwohl M, Yoles A, Lombardi K, Lou W: Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: effects on the duration of improvement. J Am Acad Dermatol 1998;39(3):447-50. 94. Lebwohl M, Ellis C, Gottlieb A, Koo J, Krueger G, Linden K, Shupack J, Weinstein G: Cyclosporine consensus conference: with emphasis on the treatment of psoriasis. J Am Acad Dermatol 1998;39(3):464-75. 95. Jorizzo JL, Lebwohl M, Tobey RE: The efficacy of metronidazole 1% cream once daily compared with metronidazole 1% cream twice daily and their vehicles in rosacea: a double-blind clinical trial. J Am Acad Dermatol 1998;39(3):502-4. 96. Wang Y, Rosenstein B, Goldwyn S, Zhang X, Lebwohl M, Wei H: Differential regulation of P53 and Bcl-2 expression by ultraviolet A and B. J Invest Dermatol 1998;111(3):380-4. 97. Wei H, Bowen R, Zhang X, Lebwohl M: Isoflavone genistein inhibits the initiation and promotion of two-stage skin carcinogenesis in mice. Carcinogenesis 1998;19(8):1509-14. 98. Lebwohl MG, Breneman DL, Goffe BS, Grossman JR, Ling MR, Milbauer J, Pincus SH, Sibbald RG, Swinyer LJ, Weinstein GD, Lew-Kaya DA, Lue JC, Gibson JR, Sefton J. 26 Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis. J Acad Dermatol 1998;39(4 Pt 1):590-6. 99. Lebwohl M, Poulin Y: Tazarotene in combination with topical corticosteroids. J Am Acad Dermatol 1998;39(4 Pt 2):S139-43. 100. . Lebwohl M: New horizons in the management of psoriasis: introduction. Cutis 1998;61(2 Suppl):7. 101. Lebwohl M: Clinical efficacy and safety of tazarotene: optimizing clinical results. Cutis 1998;61(2 Suppl):27-9. 102. Uitto J, Boyd CD, Lebwohl MG, Moshell AN, Rosenbloom J, Terry S: International Centennial Meeting on Pseudoxanthoma Elasticum: progress in PXE research. J Invest Dermatol 1998;110(5):840-2. 103. Tan MH, Lebwohl M: Psoriasis. Drugs Today 1998; 34(7):641-7. 104. Lebwohl M: Clinical efficacy and safety of Tazarotene: Optimizing clinical results. Cutis 1998;61:27-9. 105. Lebwohl M: Anthralin. Dermatol Therapy 11:8-13, 1999. 106. Sicari MC, Lebwohl M, Baral J, Wexler P, Gordon RE, Phelps RG: Photo-induced dermal pigmentation in patients taking tricyclic antidepressants: histology, electron microscopy, and energy dispersive spectroscopy. J Am Acad Dermatol 1999; 40(2 Pt 2):290-3. 107. Lebwohl M: The role of salicylic acid in the treatment of psoriasis. Int J Dermatol 1999;38(1):16-24. 108. Abrams JR, Lebwohl MG, Guzzo CA, Jegasothy BV, Goldfarb MT, Goffe BS, Menter A, Lowe NJ, Krueger G, Brown MJ, Weiner RS, Birkhofer MJ, Warner GL, Berry KK, Linsley PS, Krueger JG,Ochs HD, Kelley SL, Kang S. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999;103(9):1243-52. 109. Celebi JT, Tsou HC, Chen FF, Zhang H, Ping XL, Lebwohl MG, Kezis J, Peacocke M. Phenotypic findings of Cowden syndrome and Bannayan-Zonana syndrome in a family associated with single germine mutation in PTEN. J Med Genet 1999;36(5)360-4. 110. Leyden J, Dunlap F. Miller B, Winters P, Lebwohl M, Hecker D, Kraus S, Baldwin H, Shalita A, Draelos Z, Markou M, Thiboutot D, Rapaport M, Kang M, Kelly T, Pariser D, Webster G, Hordinsky M, Rietschel R, Katz HI, Terranella L, Best S, Round E, Waldstreicher J: Finasteride in the treatment of men with frontal male pattern hair loss. J Am Acad Dermatol 1999;40(6 Pt 1):930-7. 111. Lim HW, Anderson TF, Douglass M, Koo J, Lebwohl M, Morison W, Taylor C, Zanolli M: Cost effectiveness of methotrexate and Goeckerman: a flawed analysis. Arch Dermatol 1999;135(6):717-8. 27 112. Wei H, Zhang X, Zhao JF, Wang ZY, Bickers D, Lebwohl M: Scavenging of hydrogen peroxide and inhibition of ultraviolet light-induced oxidative DNA damage by aqueous extracts from green and black teas. Free RadicalBiol Med 1999;26(11-12):1427-35. 113. Koo J, Lebwohl M: Duration of remission of psoriasis therapies. J Am Acad Dermatol 1999;41(1):51-9. 114. Salasche SJ, Lebwohl M: Clinical pearl: vitamin E (alpha-tocopherol), 800 IU daily, may reduce retinod toxicity. J Am Acad Dermatol 1999;41(2 Pt 1):260. 115. Liu Z, Lu Y, Lebwohl M, Wei H: PUVA (8-methoxy-psoralen plus ultraviolet A) induces the formation of 8-hydroxy-2’-deoxyguanosine and DNA fragmentation in calf thymus DNA and human epidermoid carcinoma cells. Free Radical Biol Med 1999;27 (1-2):127-33. 116. Sherer DW, Sapadin AN, Lebwohl MG: Pseudoxanthoma elasticum: an update. Dermatol 1999;199(1):3-7. 117. Lebwohl M: Acitretin in combination with UVB or PUVA. J Am Acad Dermatol 1999;41(3 Pt 2):S22-4. 118. Lebwohl M: A comparison of once-daily application of mometasone furonate 0.1% cream compared with twice-daily hydrocortisone valerate 0.2% cream in pediatric atopic dermatitis patients who failed to respond to hydrocortisone: mometasone furoate study group. Int J Dermatol 1999; 38(8):604-6. 119. Rosenstein BS, Phelps RG, Weinstock MA, Bernstein JL, Gordon ML, Rudikoff D, Kantor I, Shelton R, Lebwohl MG: p53 mutations in basal cell carcinomas arising in routine users of sunscreens. PhotochemPhotobio 1999;70(5):798-806. 120. Hecker D, Worsley J, Yueh G, Kuroda K, Lebwohl M: Interactions between tazarotene and ultraviolet light. J Am Acad Dermatol 1999;41(6):927-30. 121. Savin R, Eisen D, Fradin MS, Lebwohl M: Tinea versicolor treated with terbinafine 1% solution. Int J Dermatol 1999;38(11):863-5. 122. Le Saux O, Urban Z, Göring HHH, Csiszar K, Pope FM, Richards A, Pasquali-Ronchetti I, Terry S, Bercovitch L, Lebwohl MG, Breuning M, van den Berg P, Kornet L, Ott J, de Jong PT, Bergen AA, Boyd CD: Pseudoxanthoma elasticum maps to an 820-kb region of the p13.1 region of chromosome 16. Genomics 1999;62(1):1-1. 123. Lebwohl M, Gelfand JM, Tan MH: Clinically significant therapeutic interactions for the practicing dermatologist. Adv Dermatol 14:1-26, 1999. 124. Lebwohl MG: Topical retinoid therapy plus topical corticosteroid therapy. Cutis 63(3S):8-11, 1999. 28 125. Sherer D, Kong J, Waldorf H, Lebwohl M: Laser therapy in the treatment of resistant psoriatic plaques. Aesthetic Dermatol Cosmetic Surg 1(1):43-48, 1999. 126. Lebwohl M, Lane A, Savin R, Drake L, Berman B, Lucky A, Kang S, Stuart S, Katz I, Zaias N: A comparison of once-daily application of mometasone furoate 0.0% cream compared with twice-daily hydrocortisone valerate 0.2% cream in pediatric atopic dermatitis patients who failed to respond to hydrocortisone. Int J Dermatol 1999;38:604-6. 127. Lebwohl M: Advances in psoriasis therapy. Clin Dermatol 18(1):13-9, vii, 2000. 128. Berkowitz EZ, Lebwohl M: Cutaneous manifestations of inflammatory bowel disease. J Eur Acad Dermatol Venereol 2000;14(5):349-50. 129. Gottlieb A, Krueger J, Bright R, Ling M, Lebwohl M, Kang S, Feldman S, Spellman M, Wittkowski K, Ochs HD, Jardieu, Bauer R, White M, Dedrick R, Garovoy M: Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J Am Acad Dermatol 2000;42(3):428-35. 130. Urbán Z, Peyrol S, Plauchu H, Zabot MT, Lebwohl M, Schilling K, Green M, Boyd CD, Csiszar K: Elastin gene deletions in Williams syndrome patients result in altered deposition of elastic fibers in skin and a subclinical dermal phenotype. Pediatr Dermatol 2000;17(1):12-20. 131. Lebwohl M: From the literature: intralesional 5-FU in the treatment of hypertrophic scars and keloids: clinical experience. J Am Acad Dermatol 2000;42(4):677. 132. Lebwohl M, Bernhard JD: The case for micrographically controlled skin surgery. J Am Acad Dermatol 2000;42(4):696-7. 133. Smith KC, Lebwohl M: Topical antipsoriatics. Skin Therapy Lett 2000; 5(2):1-2. 134. Cai L, Struk B, Adams MD, Ji W, Haaf T, Kang HL, Dho SH, Xu X, Ringpfeil F, Nancarrow J, Zäch S, Schaen L, Stumm M, Niu T, Chung J, Lunze K, Verrecchia B, Goldsmith LA, Viljoen D, Figuera LE, Fuchs W, Lebwohl M, Uitto J, Richards R, Hohl D, Ramesar R: A 500-Kb region on chromosome 16p13.1 contains the pseudoxanthoma elasticum locus: high- resolution mapping and genomic structure. J Mol Med 2000; 78(1):36-46. 135. Ringpfeil F, Lebwohl MG, Christiano A, Uitto J: Pseudoxanthoma elasticum: mutations in the MRP6 gene encoding a transmembrane ATP-binding cassette (ABC) transporter. Proc Natl Acad Sci USA 2000;97(11):6001-6. 136. Hecker D, Worsley J, Yueh G, Lebwohl M. In vitro compatibility of tazarotene with otheer topical treatments of psoriasis. J Am Acad of Dermatol 2000;42(6):1008-11. 137. Goldstein AE, Lebwohl M, Wei H. Comparison of urinary 8-hydroxy-2’-deoxyguanosine in patients treated with topical corticosteroids, UV-B, and psoralen UV-A therapies. Arch Dermatol 2000;136(6):808-10. 29 138. Lebwohl M: Strategies to optimize efficacy, duration of remission, and safety in the treatment of plaque psoriasis by using tazarotene in combination with a corticosteroid. J Am Acad Dermatol 2000; 43(2 Pt 3):S43-6. 139. Krueger GG, Feldman SR, Camisa C, Duvic M, Elder JT, Gottlieb AB, Koo J, Krueger JG, Lebwohl M, Lowe N, Menter A, Morison WL, Prystowsky JH, Shupack JL, Taylor JR, Weinstein GD, Barton TL, Rolstad T, Day RM: Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol 2000;43(2 Pt 1):281-5. 140. Buka R, Wei H, Sapadin A, Mauch J, Lebwohl M, Rudikoff D: Pseudoxanthoma elasticum and calcinosis cutis. J Am Acad Dermatol 2000;43(2 Pt 1):312-15. 141. Abrams JR, Kelley SL, Hayes E, Kikuchi T, Brown MJ, Kang S, Lebwohl MG, Guzzo CA, Jegasothy BV, Linsley PS, Krueger JG: Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med 2000;192(5):681-94. 142. Gottlieb AB, Lebwohl M, Shirin S, Sherr A, Gilleaudeau P, Singer G, Solodkina G, Grossman R, Gisoldi E, Phillips S, Neisler HM, Krueger JG: Anti CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebocontrolled study. J Am Acad Dermatol 2000;43(4):595-604. 143. Fleischmajer R, Kuroda K, Hazan R, Gordon RE,Lebwohl MG, Sapadin AN, Unda F, Iehara N, Yamada Y: Basement membrane alterations in psoriasis are accompanied by epidermal overexpression of MMP-2 and its inhibitor TIMP-2. J Invest Dermatol 115(5):771-777, 2000. 144. Wei H, Spencer J, Gelfand J. Phelps R, Lebwohl M: The isoflavone genistein: A new agent in dermatology? Cosmetic Dermatol 2001;14(2):13-19. 145. Krueger G, Koo J, Lebwohl M, Menter A, Stern R, Rolstad T: The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey Arch Dermatol 137(3):280-284, 2001. 146. Lebwohl M, Feldman SR, Walther R, Shelk J, Morgan P, Gutkin SW: Clinical management of psoriasis: principles and practice Cutis 2001; 67(1S):1-15. 147. Lebwohl M: Efficacy and safety of terbinafine 1% solution in the treatment of interdigital tinea pedis and tinea corporis/cruris. Cutis 67(3):261-266, 2001. 148. Lebwohl M, Feldman SR, Walther R, Shelk J, Morgan P, Gutkin SW: Clinical management of psoriasis: Principles and practice. Cutis 67(Suppl): 1-15, 2001. 149. Lebwohl M, Lombardi K, Tan MH. Duration of improvement in psoriasis after treatment with tazarotene 0.1% gel plus clobetasol propionate 0.05% ointment: comparison of maintenance treatment Int J Dermatol 40(1):64-66, 2001. 30 150. Krupnick A, Lebwohl M: VaniqaTM: A new prescription cream for unwanted facial hair in women. Cosmetic Dermatol 14(6):31-32, 2001. 151. Sherer DW, Bercovitch L, Lebwohl M: Pseudoxanthoma elasticum: significance of limited phenotypic expression in parents of affected offspring. J Am Acad Dermatol 44(3):534-537, 2001. 152. Lebwohl M, Tan M-H, Meador SL, Singer G: Limited application of fluticasone propionate ointment, 0.005% in patients with psoriasis of the face and intertriginous areas. J Am Acad Dermatol 44(1):77-82, 2001. 153. Endzweig CH, Lebwohl M: OluxTM foam as a cosmetically appealing delivery system for the treatment of psoriasis. Cosmetic Dermatol 14(11):13-15, 2001. 154. Lebwohl M, Elewski B, Eisen D, Savin RC: Efficacy and safety of terbinafine 1% solution in the treatment of interdigital tinea pedis and tinea corporis or tinea cruris. Cutis 67(3):261-266, 2001. 155. Kuroda K, Sapadin A, Shoji T, Fleischmajer R, Lebwohl M: Altered expression of angiopoietins and Tie2 endothelium receptor in psoriasis. J Invest Dermatol 2001; 116(5):713-20. 156. Tan MH, Gordon M, Lebwohl O, George J, Lebwohl M: Improvement of pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor-α monoclonal antibody. Arch Dermatol 2001;137(7):930-3. 157. Lamba S, Lebwohl M: Combination therapy with vitamin D analogues. Br J Dermatol 2001; 144(Suppl. 58): 27-32. 158. Tan MH, Lebwohl M, Esser AC, Wei H: The penetration of 0.005% fluticasone propionate ointment in eyelid skin. J Am Acad Dermatol 2001;45(3):392-6. 159. Lebwohl MG, Daniel CR, Leyden J, Mormon M, Shavin JS, Tschen E, Weiss J, Zone J: Efficacy and safety of terbinafine for nondermatophyte and mixed nondermatophyte and dermatophyte toenail onychomycosis. Int J Dermatol 2001;40(5):358-60. 160. Lebwohl M, Ali S. Treatment of Psoriasis. Part 1. Topical therapy and phototherapy. J Am Acad Dermatol 2001; 45(4):487-98, quiz 499-502. 161. Lebwohl M, Drake L, Menter A, Koo J, Gottlieb AB, Zanolli M, Young M, McClelland P: Consensus conference. acitretin in combination with UVB or PUVA in the treatment of psoriasis. J Am Acad Dermatol 2001; 45(4):544-53. 162. Stein H, Lebwohl M: Acne therapy: clinical pearls. Semin Cutan Med Surg 2001;20(3):184-9. 163. Lebwohl M, Ali S. Treatment of Psoriasis. Part 2. Systemic therapies J Am Acad Dermatol 2001;45(5):649-461; quiz 662-4. 31 164. Blum RR, Rahimizadeh A, Kardon N, Lebwohl M, Wei H. Genital lentifines in a 6-year-old boy with a family history of Cowden’s disease: clinical and genetic evidence of the linkage between Bannayan-Riley-Ruvacalba syndrome and Cowden’s disease. J Cutan Med Surg 2001;5(3):228-30. 165. Galadari I, Rigel E, Lebwohl M: The cost of psoriasis treatment. J Eur Acad Dermatol Venereol 2001; 15(4):290-1. 166. Wong VK, Lebwohl M. What cosmetic dermatologists should know about the new biologic agents for psoriasis treatment. Cosmetic Dermatol 15(11):33-34, 2002. 167. Lebwohl M. Introduction. Optimizing therapy for psoriatic patients with calcipotriene. Cutis 70(5Suppl):3-4, 2002. 168. Stern DK, Lebwohl M. Treatment of mycosis fungoides with oral bexarotene combined with PUVA. J Drugs Dermatol 2002;1(2) :134-6. 169. Ellis CN, Drake LA, Prendergast MM, Abramovits W, Boguniewicz M, Daniel CR, Lebwohl M, Stevens SR, Whitaker-Worth DL, Cheng JW, Tong KB: Cost of atopic dermatitis and eczema in the United States. J Am Acad Dermatol 2002; 46(3):361-70. 170. Shyong EQ, Lu Y, Lazinsky A, Saladi R, Phelps RG, Austin LM, Lebwohl M, Wei H. Effects of the isoflavone 4’,5,7-trihydroxyisoflavone (genistein) on psoralen plus ultraviolet A radiation (PUVA)-induced photodamage. Carcinogenesis. 2002 ; 23(2):317-21. 171. Bershad S, Kranjac Singer G, Parente JE, Tan MH, Sherer DW, Persaud AN, Lebwohl M: Successful treatment of acne vulgaris using a new method: results of a randomized vehiclecontrolled trial of short-contact therapy with 0.1% tazarotene gel. Arch Dermatol 2002; 138(4):481-9. 172. Endweig-Gribetz CH, Brady C, Lynde C, Sibbald D, Lebwohl M: Drug interactions in psoriasis: the pros and cons of combining topical psoriasis therapies. J Cutan Med Surg 2002; 6(3 Suppl):12-6. 173. Lebwohl M: Should we switch from combination UVA/UVB phototherapy unit to narrowband UVB? Photodermatol Photoimmunol Photomed 2002; 18(1):44-6; discussion 47-9. 174. Sherer DW, Lebwohl MG: 6-thioguanine in the treatment of psoriasis: a case report and literature review. J Cutan Med Surg 2002; 6(6):546-5. 175. Lebwohl M. New developments in the treatment of psoriasis. Arch Derm2002;138(5):686-8. 176. Lebwohl M, Sherer D, Washenik K, Krueger GG, Menter A, Koo J, Feldman SR. A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis. Int J Dermatol 2002; 41(5):269-74. 32 177. Wei H, Zhang X. Wang Y, Lebwohl M: Inhibition of ultraviolet light-induced oxidative events in the skin and internal organs of hairless mice by isoflavone genistein. Cancer Lett 2002; 185(1):21-9. 178. Persaud A, Lebwohl M: Imiquimod cream in thetreatment of actinic keratoses. J Am Acad Dermatol 2002; 47(4Suppl):S236-9. 179. Persaud AN, Shamuelova E, Sherer D, Lou W, Singer G, Cervera C, Lamba S, Lebwohl MG: Clinical effect of imiquimod 5% cream in the treatment of actinic keratosis. J Am Acad Dermatol 2002; 47(4):553-6. 180. Gottlieb AB, Lebwohl M, Totoritis MC, Abdulghani AA, Shuey SR, Romano P, Chaudhari U, Allen RS, Lizambri RG: Clinical and histologic response to a single-dose treatment of moderate to severe psoriasis with an anti-CD80 monoclonal antibody. J Am Acad Dermatol 2002; 47(5):692-700. 181. Tan MH, Meador SL, Singer G, Lebwohl M: An open-label study of the safety and efficacy of limited application of fluticasone propionate ointment, 0.005%, in patients with atopic dermatitis of the face and intertriginous areas Int J Dermatol 2002; 41(11):804-9. 182. Lebwohl M: Vitamin D and topical therapy. Cutis 2002; 70(5 Suppl):5-8. 183. Shyong EQ, Gorevic P, Lebwhol M, Phelps RG. Reactive angioendo-theliomatosis and sarcoidosis. Int J Dermatol 2002; 41(12):894-97. 184. Saladi R, Austin L, Gao D, Lu Y, Phelps R, Lebwohl M: The combination of benzo[a]pyrene and ultraviolet A causes an in vivo time-related accumulation of DNA damage in mouse skin. Photochem and Photobio 77(4): 413-9, 2003. 185. Blum RR, Wong VK, Lebwohl M. Alefacept – revolutionizing psoriasis therapy. J New Develop Clin Med 21(2):97-116, 2003. 186. Kwan V, Della Croce C, Schonfeld S, Mastrangelo AM, Lebwohl M. Use and abuse of topical corticosteroids in infections of the skin and related structures. J Drugs Dermatol 3:268-276, 2003. 187. Rigel EG, Lebwohl MG, Rigel AC, Rigel DS. Ultraviolet radiation in alpine skiing: magnitude of exposure and importance of regular protection. Arch Dermatol 2003; 139(1):60-2. 188. Bercovitch L, Schepps B, Koelliker S, Magro C, Terry S, Lebwohl M: Mammographic findings in pseudoxanthoma elasticum J Am Acad Dermatol 2003; 48(3):359-66. 189. Galadari H, Fuchs B, Lebwohl M. Newly available treatments for psoriatic arthritis and their impact on skin psoriasis Int J Dermatol 2003; 42(3):231-37. 190. Ellis CN, Drake LA, Prendergast MM, Abramovits W, Boguniewicz M, Daniel CR, Lebwohl M, Paller AS, Stevens SR, Whitaker-Worth DL, Tong KB. Cost-effectiveness analysis of tacrolimus ointment versus high-potency topical corticosteroids in adults with moderate-to-severe 33 atopic dermatitis. J Am Acad Dermatol 2003; 48(4):553-63. 191. Freeman AK, Linowski G , Brady C, Lind L, Vanveldhuisen P, Singer G, Lebwohl M. Tacrolimus ointment for treatment of psoriasis on the face and intertriginous areas. J Am Acad Dermatol 2003; 48(4):564-68. 192. Lebwohl M, Lebwohl E, Bercovitch L: Prominent mental (chin) crease: A new sign of pseudoxanthoma elasticum. J Am Acad Dermatol 2003;48(4):620-22. 193. Lebwohl M. Psoriasis. Lancet 2003;361:1197-1204. 194. Shyong EQ, Lu Y, Goldstein A, Lebwohl M, Wei H: Synergistic enhancement of H202 production in human epidermoid carcinoma cells by Benzo[a]pyrene and ultraviolet A radiation. Toxicol Appl. Pharmacol. 2003;188(2):104-9. 195. Ortonne JP, Lebwohl M, Em Griffiths C. Alefacept-induced decreases in circulating blood lymphocyte counts correlated with clinical response in patients with chronic plaque psoriasis. Eur J Dermatol 2003;13(2):117-23. 196. Saladi R, Austin L, Gao D, Lu Y, Phelps R, Lebwohl M, Wei H. The combination of benzo[a]pyrene and ultraviolet A causes an in vivo time related accumulation of DNA damage in mouse skin. Photochem Photobiol 2003;77(4):413-9. 197. Weinstein GD, Koo JY, Krueger GG, Lebwohl MG, Lowe NJ, Menter MA, Lew-Kaya DA, Sefton J, Gibson JR, Walker PS; Tazarotene Cream Clinical Study Group. Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. J Am Acad Dermatol 2003;48(5):760-67. 198. Rapaport MJ, Lebwohl M: Corticosteroid addiction and withdrawal in the atopic: The red burning skin syndrome. Clin Dermatol 2003;21(3):201-14. 199. Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CE. An international, randomized, double-blind, placebo-controlled Phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003;139(6):719-27. 200. Wong VK, Della Croce C, Schonfeld S, Mastrangelo AM, Lebwohl M. Use and abuse of topical corticosteroids in infections of the skin and related structures. Drugs Dermatol 2003;2(3):268-76. 201. Kazlow DW, Federgrun D, Kurtin S, Lebwohl M: Cutaneous ulceration caused by methotrexate. J Am Acad Dermatol 2003;49(3); S197-8. 202. Lebwohl M. Combining the new biologic agents with our current psoriasis armamentarium. J Am Acad Dermatol 2003;49(2); S118-24. 203. Ellis CN, Drake LA, Prendergast MM, Abramovits W, Boguniewicz M, Daniel CR, Lebwohl M, Stevens SR, Whitake-Worth DL, Tong KB. Validation of expert opinion in identifying 34 comorbidities associated with atopic dermatitis/eczema. Pharmacoeconomics 2003;21(12): 87583. 204. Lebwohl M, Quijije J, Gilliard J, Rollin T, Watts O. Topical calcitriol is degraded by ultraviolet light. J Invest Dermatol 2003;121(3): 594-5. 205. Ruzicka T, Assmann T, Lebwohl M. Potential future dermatological indications for tacrolimus ointment. Eur J Dermatol 2003;13(4); 331-42. 206. Singh F, Gao D, Lebwohl MG, Wei H. Shikonin modulates cell proliferation by inhibiting epidermal growth factor receptor signaling in human epidermoid carcinoma cells. Cancer Lett 2003;28;200(2):115-21. 207. Galadari H, Lebwohl M. Pseudoxanthoma elasticum: Temporary treatment of chin folds and lines with injectable collagen. J Am Acad Dermatol 2003;49(5); S265-6 208. Callen JP, Krueger GG, Lebwohl M, McBurney, EI, Mease P, Menter A, Paller AS, Pariser DM, Weinblatt M, Zimmerman G. Summit Planning Group. AAD consensus statement on psoriasis therapies. J Am Acad Dermatol 2003;49(5): 897-9. 209. Lebwohl M, Tannis C, Carrasco D. Acitretin suppression of squamous cell carcinoma: case report and literature review. J Dermatol Treat 2003;14(2): S3-S6. 210. Maryles S, Rozenblit M, Lebwohl M. Transition from methotrexate and cyclosporine to other therapies including retinoids, ultraviolet light and biologic agents in the management of patients with psoriasis. J Dermatol Treat 2003;14(2); S7-S16. 211. Spuls PI, Rozenblit M, Lebwohl M. Retrospective study of the efficacy of narrowband UVB and acitretin. J Dermatol Treat 2003;14(2); S17-S20. 212. Spuls PI, Hadi S, Rivera L, Lebwohl M. Retrospective analysis of the treatment of psoriasis and of the palms and soles. J Dermatol Treat 2003; 14(Suppl 2);21-5. 213. Lebwohl M, Menter A, Koo J, Feldman SR. Case studies in severe psoriasis: A clinical strategy. J Dermatol Treat. 2003;14(2); S26-S46. 214. Wei H, Saladi R, Lu Y, Wang Y, Palep SR, Moore J, Phelps R, Shyong E, Lebwohl MG. Isoflavone genistein: photoprotection and clinical implications in dermatology. J Nutr 133(11 Suppl 1); 3811S-3819S, 2003. 215. Wong VK, Lebwohl M. The use of alefacept in the treatment of psoriasis. Skin Therapy Lett 2003 ;8(6) :1-2, 7. 216. Lebwohl M. Actinic keratosis: epidemiology and progression to squamous cell carcinoma. Br J Dermatol 2003;149 Suppl 66:31-3. 217. .Ku S, Lebwohl M: Classification of psoriasis by its natural history: A new perspective from abroad. Psoriasis Forum 2003;9(1). 35 218. Lebwohl M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH, Walicke P, Dummer W, Wang X, Garovoy MR, Pariser D. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Eng J Med 349(2); 2004-2013, 2003. 219. Rigel EG, Lebwohl M, Rigel AC, Rigel DS. Daily UVB exposure levels in high-school students measured with digital dosimeters J Am Acad Dermatol 2003;49(6); 1112-4. 220 . Fuchs A, Fiedler J, Lebwohl M, Sapadin A, Rudikoff D, Lefkovits A, Schultz N, Khorenian S, Kakita L. Frequency of culture-proven dermatophyte infection in patients with suspected tinea pedis. Am J Med Sci 2004; 327(2):77-8. 221. Lebwohl M, Menter A, Koo J, Feldman SR. Combining therapy to treat moderate to severe psoriasis. J Am Acad Dermatol 2004;50(3):416-30 222. Koo J, Lee E, Lee CS, Lebwohl M. Psoriasis J Am Acad Dermatol 2004; 50(4):613-22. 223. Fazekaas Z, Gao D, Saladi RN, Lu Y, Lebwohl M, Wei H. Protective effects of lycopene against untraviolet B-induced photodamage. Nutr Cancer 2003;47(2):181-7. 224. Gottlieb AB, Kang W, Linden KG, Lebwohl M, Menter A, Abdulghani AA, Goldfarb M, Chieffo N, Totoritis MC. Evaluation of safety and clinical activity of multiple doses of the antiCD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis. Clin Immunol 2004; 111(1):28-37. 225. Lebwohl M, Dinehart S, Whiting D, Lee PK, Tawfik N, Jorizzo J, Lee JH, Fox TL. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, doubleblind, parallel group, vehicle-controlled trials. J Am Acad Dermatol 2004; 50(5):714-21. 226. Freeman AK, Serle J, VanVeldhuisen P, Lind L, Clarke J, Singer G, Lebwohl M. Tacrolimus ointment in the treatment of eyelid dermatitis. Cutis 2004;73(4): 267-71. 227. Hadi SM, Spencer JM, Lebwohl M. The use of the 308-nm excimer laser for the treatment of vitiligo. Dermatol Surg 2004; 30(7):983-6. 228. Lebwohl M. Innovations in the treatment of psoriasis. J Am Acad Dermatol 2004;51(1Suppl):S40-1. 229. Lebwohl M, Plott T. Safety and efficacy of ciclopirox 1% shampoo for the treatment of seborrheic dermatitis of the scalp in the US population: Results of a double-blind, vehiclecontrolled trial Int J Dermatol 2004; 43(1):17-20. 230. Prendergast MM, Abramovits W, Boguniewicz M, Lebwohl M, Tokar M, Tong KB. Look beyond financial conflicts of interest in evaluating industry-academia collaborations in burdenof-illness and outcomes research studies in dermatology. J Invest Dermatol 2004;123(3):452-4. 36 231. Saladi RN, Singh F, Wei H, Lebwohl M, Phelps RG. Use of Ber-EP4 protein i recurrent metastatic basal cell carcinoma: a case report and review of the literature. Int J Dermatol 2004;43(8):600-3 232. Stebbins WG, Lebwohl MG. Biologics in combination with nonbiologics: efficacy and safety. Dermatologic Therapy 2004;17(5): 432-40. 233. Singh F, Lebwohl MG. Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: a case series. J Am Acad Dermatol. 2004; 51(4):570-73. 234. Aaronson DS, Lebwohl M. Review of therapy of psoriasis: the prebiologic armamentarium. Dermatol Clin 2004;22(4):379-88, vii. 235. Lebwohl M, Freeman AK, Chapman MS, Feldman SR, Hartle JE, Henning A; Tacrolimus Ointment Study Group. Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol 2004;51(5):731-8. 236. Gribetz C, Ling M, Lebwohl M, Pariser D, Draelos Z, Gottlieb AB, Zaias N, Chen DM, ParneixSpake A, Hultsch T, Menter A. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double blind, randomized study. J Am Acad Dermatol 2004; 51(5):731-8. 237. Moore JO, Palep SR, Saladi RN, Gao D, Wang Y, Phelps RG, Lebwohl MG, Wei H. Effects of ultraviolet B exposure on the expression of proliferating cell nuclear antigen in murine skin paragraph sign. Photochem Photobiol 2004;80(3):587-95. 238. Gottlieb AB, Gordon KB, Lebwohl MG, Caro I, Walicke PA, Li N, Leonardi CL; Efalizumab Study Group. Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis. J Drugs Dermatol 2004;3(6):614-24. 239. Gupta AK, Lebwohl M. Ciclopirox 1% shampoo is a safe and effective treatment for seborrheic dermatitis. Int J Dermatol 43(1): 1-2; 2004. 240. Wong VK, Fuchs B, Lebwohl M. Overview on desonide 0.05%: a clinical safety profile. J Drugs Dermatol 3(4):393-7, 2004. 241 Della Croce C, Wong VK, Lebwohl M. Efalizumab in the treatment of psoriasis. Therapy 1(2):197-202, 2004. 242. Lebwohl M, Wong VK, Della Croce, C. Expanding the therapeutic options for psoriatic conditions. Patient Care 38(12):46-50, 2004. 243. Lamba S, Krishtul A, Tan MH, Lebwohl MG. Acanthosis nigricans in a plaque of scleredema on the back of a diabetic patient: A case report. Int J Dermatol 2005;44(1):45-7. 244. Lebwohl M, Ting PT, Koo JYM. Psoriasis treatment: traditional therapy. Ann Rheum Dis 2005;64 (Suppl 2): ii83-6. 37 245. Wang Y, Gao D, Atencio DP, Perez E, Saladi R, Moore J, Guevara D, Rosenstein BS, Lebwohl M, Wei H. Combined subcarcinogenic benzo[a]pyrene and UVA synergistically caused high tumor incidence and mutations in H-ras gene, but not p53, in SKH-1 hairless mouse skin. Int J Cancer 2005;116(2):193-9. 246. Schwartz B, Lebwohl M. Complications of the smallpox vaccine. Int J Dermatol 2005;44:289292. 247. Kazlow Stern D, Tripp JM, Ho VC, Lebwohl M. The use of systemic immune moderators in dermatology: an update. Dermatol Clin 2005;23(2):259-300. 248. Paller AS, Lebwohl M, Fleischer AB Jr, Antaya R, Langley RG, Kirsner RS, Blum RR, Rico MJ, Jaracz E, Crowe A, Linowski GJ, US/Canada Tacrolimus Ointment Study Group. Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. J AmAcad Dermatol 2005;52(5):810-822. 249. Soung J, Muigai W, Amin N, Stern DK, Lebwohl MG. A chart review of patients with early stage mycosis fungoides treated with psoralen plus UVA (PUVA). J Drugs Dermatol 2005;4(3):290-294. 250. Breneman D, Fleischer AS Jr, Kaplan D, Lebwohl M, Miller B, Pariser D, Rist T, Swinyer L, Liu Y, Foley V. Clobetasol propionate 0.05% lotion in the treatment of moderate to severe atopic dermatitis: a randomized evaluation versus clobetasol propionate emollient cream. J Drugs Dermatol 2005;4(3):330-6. 251. McKenna SP, Lebwohl M, Kahler KN. Development of the US PSORIQoL: a psoriasis-specific measure of quality of life. Int J Dermatol 2005;44(6):462-469. 252. Hochberg MC, Lebwohl MG, Plevy SE, Hobbs KF, Yocum DE. The Benefit/Risk Profile of TNF-Blocking Agents: Findings of a Consensus Panel. Semin Arthritis Rheum. 2005;34(6):81936. 253. Gribetz CH, Blum R, Brady C, Cohen S, Lebwohl M. An extended 16-week course of alefacept in the treatment of chronic plaque psoriasis. J Am Acad Dermatol 2005;53(1):73-75. 254. Lebwohl M. A clinician’s paradigm in the treatment of psoriasis. J Am Acad Dermatol 2005;53(1 Suppl 1):S59-S69. 255. Lebwohl M, Blum R, Berkowitz E, Kim D, Zitnik R, Osteen C, Wallis WJ. No evidence for increased risk of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis receiving etanercept for up to 5 years. Arch Dermatol 2005;141(7):861-864. 256. Kang S, Bergfeld W, Gottlieb AB, Hickman J, Humeniuk J, Kempers S, Lebwohl M, Lowe N, McMichael A, Milbauer J, Phillips T, Powers J, Rodriguez D, Savin R, Shavin J, Sherer D, Silvis N, Weinstein R, Weiss J, Hammerberg C, Fisher GJ, Nighland M, Grossman R, Nyirady J. Long-term efficacy and safety of tretinoin emollient cream 0.05% in the treatment of 38 photodamaged facial skin: a two-year, randomized, placebo-controlled trial. Am J Clin Dermatol 2005;6(4): 245-253. 257. Miksch S, Lumsden A, Guenther UP, Foernzler D, Christen-Zäch S, Daugherty C, Ramesar RS, Lebwohl M, Hohl D, Neldner KH, Lindpaintner K, Richards RI, Struk B. Molecular genetics of pseudoxanthoma elasticum: type and frequency of mutations in ABCC6. Hum Mutat 2005; 26(3):235-248 258. Lebwohl M, Freeman A, Chapman MS, Feldman S, Hartle J, Henning A. Proven efficacy of tacrolimus for facial and intertriginous psoriasis. Arch Dermatol 2005;141(9):1154. 259. Sherer DW, Singer G, Uribarri J, Phelps RG, Sapadin AN, Freund KB, Yanuzzi L, Fuchs W, Lebwohl M. Oral phosphate binders in the treatment of pseudoxanthoma elasticum. J Am Acad Dermatol 2005;53(4):610-5. 260. van de Kerkhof P, Griffiths CE, Christophers E, Lebwohl M, Krueger GG. Alefacept in the treatment of psoriasis in patients for whom conventional therapies are inadequate. Dermatology 2005;211(3):256-63. 261. Gao D, Luo Y, Guevara D, Wang Y, Rui M, Goldwyn B, Lu Y, Smith EC, Lebwohl M, Wei H. Benzo[a]pyrene and its metabolites combined with ultraviolet A synergistically induce 8hydroxy-2'-deoxyguanosine via reactive oxygen species. Free Radic Biol Med 2005;39(9):117783. 262. Wong VK, Lebwohl MG. Treatment of psoriatic arthritis with etancercept, a tumour necrosis factor antagonist. Expert Opin Biol. Ther 2005;5(11):1505-13. 263. Lebwohl MG. Advances in psoriasis. Arch Dermatol. 2005;141(12):1589-90. 264. Lebwohl M, Friedlander SF. New strategies for optimizing the treatment of inflammatory dermatoses with topical corticosteroids in an era of corticosteroid-sparing regimens. J Am Acad Dermatol 2005;53(1 Pt 2):S1- S2. 265. Lebwohl M, Ting PT, Koo JY. Psoriasis treatment: traditional therapy. Ann Rheum Dis 2005;64 Suppl 2:ii83-6. 266. Lebwohl MG. Use of etanercept in the dermatology setting : a review. Am J Clin Dermatol 2005;6(1):49-59. 267. Menter A, Cather JC, Baker D, Farber HF, Lebwohl M, Darif M. The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis. J Am Acad Dermatol 2006; 54(1):61-63. 268. Ringpfeil F, McGuigan K, Fuchsel L, Kozic H, Larralde M, Lebwohl M, Uitto J. Pseudoxanthoma elasticum is a recessive disease characterized by compound heterozygosity. J Invest Dermatol 2006; 126: 782-6. 39 269. Zeichner JA, Stern DW, Lebwohl M. Treatment of necrobiosis lipoidica with the tumor necrosis factor antagonist etanercept. J Am Acad Dermatol 2006;54(3 Suppl 2):S120-121. 270. Carey W, Glazer S, Gottlieb AB, Lebwohl M, Leonardi C, Menter A, Papp K, Rundle AC, Toth D. Relapse, rebound, and psoriasis adverse events: An advisory group report. J Am Acad Dermatol 2006; 54(4):S171-S181. 271. Moore JO, Wang Y, Stebbins WG, Gao D, Zhou X, Phelps R, Lebwohl M, Wei H. Photoprotective effect of isoflavone genistein on ultraviolet B induced pyrimidine dimer formation and PCNA expression in human reconstituted skin and its implications in dermatology and prevention of cutaneous carcinogenesis. Carcinogenesis 2006;27(8):1627-35. 272. Rigel AS, Lebwohl MG. Hat-wearing patterns in persons attending baseball games. J Am Acad Dermatol 2006;54(5):918-9. 273. Otley CC, Stasko T, Tope WS, Lebwohl M. Chemoprevention of nonmelanoma skin cncer with systemic retinoids: practical dosing and management of adverse effects. Dermatol Surg 2006; 32(4):562-8. 274. Pariser DM, Gordon KB, Papp KA, Leonardi CL, Kwon P, Compton PG, Rundle AC, Walicke PA, Lebwohl M. Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled phase III trials: part I. J Cutan Med Surg 2005;9(6):303-12. 275. Lebwohl M, Kathryn M. New roles for systemic retinoids. J Drugs Dermatol 2006; 5(5):406-9. 276. Smith E, Gordon M, Lebwohl M. Calcinosis cutis in a patient with eosinophilia myalgia syndrome: a case report. Cutis 2006; 77(6):361-4. 277. Lebwohl M, Herrmann LG. Impaired skin barier function in dermatologic disease and repair with moisturization. Cutis 2005;76: 7-12. 278. Hadi S, Tinio P, Al-Ghaithi K, Al-Qari H, Al-Helalat M, Lebwohl M, Spencer J. Treatment of vitiligo using the 308-nm excimer laser. Photomed Laser Surg 2006;24(3):354-7. 279. Koo J, Blum RR, Lebwohl M. A randomized, multicenter study of calcipotriene ointment and clobetasol propionate foam in the sequential treatment of localized plaque-type psoriasis: shortand long-term outcomes. J Am Acad Dermatol 2006;55(4):637-41. 280. Koo K, Brem H, Lebwohl M. Pyoderma gangrenosum versus ulceration: comparison of diagnostic features. J Cutan Med Surg 2006; 10(1):26-30. 281. Halverstam CP, Zeichner J, Lebwohl M. Lack of significant skeletal changes after long-term, low-dose retinoid therapy: case report and review of the literature. J Cutan Med Surg 2006;10(6):291-9. 282. Lebwohl M. Combining dermatologic therapies: what works and what doesn’t. Skin & Aging 2006;May: 14-16. 40 283. Lebwohl M, Callen J. Obesity, smoking and psoriasis. JAMA 2006;295:208-10. 284. Krueger GG, Langley RG, Leonard C, Yeilding N, Guzzo C, Wang Y, Dooley Lt, Lebwohl M; CNTO 1275 Psoriasis Study Group. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007;356(6):580-92. 285. Pariser DM, Bagel J, Gelgand JM, Korman NJ, Ritchlin CT, Strober BE, van Voorhees AS, Young M, Rittenberg S, Lebwohl MG, Horn EJ, National Psoriasis Foundation clinical consensus on disease severity. Arch Dermatol 2007;143(2):239-42. 286. Lebwohl MG. Advances in first-line topical therapies: the role of a 2-compound ointment for psoriasis vulgaris. Cutis 200779 1S[ii] 3-4. 287. Lebwohl MG, Corvari L. Compatibiliy of topical therapies for psoriasis: Challenges and innovations. Cutis 2007;79 1S[ii] 5-10. 288. Stern D, Diamantis S, Smith E, Wei H, Gordon M, Muigai W. Moshier E, Lebwohl M, Spuls P. The water content and other aspects of brittle versus normal fingernails. J Am Acad Dermatol 2007;57(1):31-6. 289. Lebwohl M, Gower T. A safety assessment of topical calcineurin inhibitors in the treatment of atopic dermatitis. MedGenMed 2006;8(4):8. 290. Zeichner JA, Lebwohl M. Potential compliations associated with the use of biologic agents for psoriasis. Dermatol Clin 2007; 25:207-13. 291. Lebwohl M, Clark L, Levitt J. Therapy for head lice based on life cycle, resistance, and safety considerations. Pediatrics. 2007;119(5):965-74. 292. Uliasz A, Lebwohl M. Patient education and regular surveillance results in earlier diagnosis of second primary melanoma. Int J Dermatol 2007; 46(6):575-7. 293. Lebwohl M, Menter A, Weiss J, Clark SD, Flores J, Powers J, Balin AK, Kempers S, Glinert RJ, Fleming T, Liu Y, Graeber M, Pariser DM. Calcitriol 3 uG/G ointment in the management of mild to moderate plaque type psoriasis: Results from 2 placebo-controlled, multicenter, randomized, double-blind clinical studies. J Drugs Dermatol 2007;6(4): 428-35. 294. Horn EJ, Fox KM, Patel V, Chiou CF, Dann F, Lebwohl M. Are patients with psoriasis undertreated? Results of National Psoriasis Foundation survey. J Am Acad Dermatol 2007;57(6):957-62. 295. Clark L, Lebwohl M. Recent advances in medical dermatology. Int J Dermatol 2007;46(10):1005-10. 296. Lebwohl M, Pariser DM (eds): Management of nonmelanoma skin cancer in high-risk populations. Skin & Aging (Suppl) July 2007. 41 297. Lebwohl M, Bagel J, Gelfand JM, Gladman D, Gordon KB, Hsu S, Kalb RE, Kimball AB, Korman NJ, Krueger GG, Mease P, Morison WL, Paller A, Pariser DM, Ritchlin C, Strober B, Van Voorhees A, Weinstein GD, Young M, Horn L: From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. J Am Acad Dermatol 2008;58(1):94-105. 298. Clark L, Lebwohl M. The effect of weight on the efficacy of biologic therapy in patients with psoriasis. J Am Acad Dermatol 2008;58(3):443-6. 299. Lebwohl M, Colón LE. The evolving role of topical treatments in adjunctive therapy for moderate to severe plaque psoriasis. Cutis 2007; 80(5 Suppl):29-40. 300. Wang Y, Zhou X, Weinstein E, Maryles B, Zhang Y, Moore J, Gao D, Atencio DP, Rosenstein BS, Lebwohl M, Chen HD, Xiao T, Wei H.p53 gene mutations in SKH-1 mouse tumors differentially induced by UVB and combined subcarcinogenic benzo[a]pyrene and UVA. Photochem Photobiol 2008;84(2):444-9. Epub 2008 Jan 29. 301. Breneman D, Fleischer AB Jr, Abramovits W. Zeichner J, Gold MH, Kirsner RS, Shull TF,Crowe AW, Jaracz E, Hanifin JM; Tacrolimus Ointment Study Group. Intermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis: a randomized comparison of 3-times-weekly applications of tacrolimus ointment versus vehicle. J Am Acad Dermatol 2008;58(6):990-222. 302. Horn EJ, Fox KM, Patel V, Chiou CF, Dann F, Lebwohl M. Association of patient-reported psoriasis severity with income and employment. J Am Acad Dermatol 2007;57(6):963-71. 303. Kimball AB, Gladman D, Gelfand JM, Gordon K, Horn EJ, Korman NJ, Korver G, Krueger GG, Strober BE, Lebwohl MG; National Psoriasis Foundation. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 2008;58(6):1031-42. Epub 2008 Mar 4. 304. Lebwohl M. What is known about the association of antinuclear antibodies development during treatment with TNF blockers?” J Clin Aesthetic Dermatol 2008; 1(31): 44-5. 305. Patel V, Horn EJ, Lobosco SJ, Fox KM, Stevens SR, Lebwohl M: Psoriasis treatment patterns: results of a cross-sectional survey of dermatologists. J Am Acad Dermatol 2008;58(6):964-9. Epub 2008 Apr 18. 306. Smith EC, Riddle C, Menter MA, Lebwohl M. Combining systemic retinoids with biologic agents for moderate to severe psoriasis. Int J Dermatol 2008;47(5):514-8. 307. Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, Lebwohl M, Koo JY, Elmets CA, Korman NJ, Beutner KR, Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008;58(5):826-50. 308. Gottlieb A, Korman NJ, Goardon KB, Feldman SR, Lebwohl M, Koo JY, Van Voorhees AS, Elmets CA. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. 42 Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008;58(5):851-64. 309. Doherty SD, Van Voorhees A, Lebwohl MG, Korman NJ, Young MC, Hsu S. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. J Am Acad Dermato 2008;59(2):209-17. Epub 2008 May 15. 310. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yielding N, Guzzo C, Hsu MC, Wang Y, Li S, Dooley LT, Reich K; PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008;371(9625):1675-84. 311. Uliasz A, Lebwohl M.Cutaneous manifestations of cardiovascular diseases. Clin Dermatol 2008;26(3):243-54. 312. Uliasz A, Zeichner J, Soung J, Lebwohl M. A single-center, double-blind, randomized trial of the atrophogenic effects of fluocinonide cream 0.1% versus clobetasol propionate cream 0.05% in participants with corticosteroid-responsive dermatoses. Cutis 2008;81(6):517-9. 313. Uliasz A, Lebwohl M. A new standardized method of evaluating cutaneous irritation from topical medications. Cutis 2008;82(1):75-7. 314. Halverstam CP, Lebwohl M. Nonstandard and off-label therapies for psoriasis. Clin Dermatol 2008;26(5):546-53. 315. Kaufman ED, Lebwohl MG, Krueger GG, Zimmerman G, Horn EJ, Feldman SR. What the National Psoriasis Foundation means to dermatologists and our patients. Cutis 2008;82(3): 181-3. 316. Zeicher JA, Stern DW, Uliasz A, Itenberg S, Lebwohl M. Placebo- controlled, double-blind, randomized pilot study of imiquimod 5% cream applied once per week for 6 months for the treatment of actinic keratoses. J Am Acad Dermatol 2009;60(1):59-62. Epub 2008 Oct 19. 317. Paller AS, Eichenfield LF, Kirsner RS, Shull T, Jaracz E, Simpson EL; US Tacrolimus Ointment Study Group. Three times weekly tacrolimus ointment reduces relapse in stabilized atopic dermatitis: a new paradigm for use. Pediatrics 2008;122(6):e1210-8. Epub 2008 Nov 17. 318. Kalb RE, Bagel J, Korman NJ, Lebwohl MG, Young M, Horn EJ, Van Voorhees AS; National Psoriasis Foundation. Treatment of intertriginous psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2009; 60(1):120-4. 319. Rozenblit M, Lebwohl M. New biologics for psoriasis and psoriatic arthritis. Dermatol Ther 2009;22(1):56-60. 320. Mentor A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gotttlieb A, Koo JY, Lebwohl M, Lim HW, Van Voorhees AS, Beutner KR, Bhushan R. Guidelines of care for the 43 management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol 2009;60(4):643-59. Epub 2009 Feb 13. 321. Lebwohl M, Ortonne JP, Andres P. Briantais P. Calcitriol ointment 3 microg/g is safe and effective over 52 weeks for the treatment of mild to moderate plaque psoriasis. Cutis 2009;83(4):205-12. 322. Kalb RE, Strober B, Weinstein G, Lebwohl M. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 2009;60(5):824-37. 323. Chan CS, Van Voorhees AS, Lebwohl MG, Korman NJ, Young M, Bebo BF Jr, Kalb RE, Hsu S. treatment of severe scalp psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2009;60(6):962-71. 324. Patel RV, Clark LN, Lebwohl M, Weinberg JM. Treatments for psoriasis and the risk of malignancy: A review. J Am Acad Dermatol 2009; 60(6):1001-17. 325. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb AB, Koo JY, Lebwohl M, Lim HW, Van Voorhees AS, Beutner KR, Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis Section 4: Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009;61(3):451-85. 326. Frankel AJ, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl MG, Bebo BF Jr, Gottlieb AB; National Psoriasis Foundation. Treatment of psoriasis in patients with hepatitis C: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2009;61(6):1044-55. 327. Menon K, Van Voorhees AS, Bebo BF Jr, Gladman DD, Hsu S, Kalb RE, Lebwohl MG, Strober BE; for the National Psoriasis Foundation. Psoriasis in patient with HIV infection: From the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2010;62(2):291-9. 328. Rosenbach M, Hsu S, Korman NJ, Lebwohl MG, Young M, Bebo BF Jr, Van Voorhees AS. Treatment of erythrodermic psoriasis: From the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2010;62(4):655-62 329. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb A, Koo JY, Lebwohl M, Lim HW, van Voorhees AS, Beutner KR, Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol 2010;62(1):114-35. Epub 2009 Oct 7. 330. Lebwohl M, Papp K, Han C, Schenkel B, Yeilding N, Wang Y, Krueger GG. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial. Br J Dermatol 2010;162(1):137-46. Epub 2009 Nov 331. Rosmarin DM, Lebwohl M, Elewski BE, Gottlieb AB. Cyclosporine and psoriasis: 2008 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 2010;62(5):838-53. 44 Epub 2009 Nov 24. 332. Chaarani J, Lebwohl M. Alefacept; where it stands today. Expert Opin Drug Metab. 2010;6(3):355-61. 333. Kling M, Larian A, Scordi-Bello I, Emer J, Lebwohl M. Fatal H1N1 viral respiratory infection in a patient with psoriasis treated with infliximab. Arch Dermatol 2010;146(6):651-4. 334. Horn EJ, Domm S, Katz HI, Lebwohl M, Mrowietz U, Kragballe K; International Psoriasis Council. Topical corticosteroids in psoriasis: strategies for improving safety. J Eur Acad Dermatol Venereol 2010;24(2):119-24. Epub 2009 Jul 3. 335. Alsufyani MA, Golant AK, Lebwohl M. Psoriasis and the Metabolic Syndrome. Dermatol Ther 2010;23:137-43. 336. Bremmer S, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl MG, Young M, Bebo BF Jr, Blauvelt A; National Psoriasis Foundation. Obesity and psoriasis: From the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2010;63(6):1058-69. Epub 2010 Aug 7 337. Lebwohl M, Yeilding N, Szaparty P, Wang Y, LiS, Zhu Y, Reich K, Langley RG, Papp KA. Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: Rationale for dosing recommendations. J Am Acad Dermatol 2010 Jul 2. [Epub ahead of print] 338. Levine D, Even-Chen Z, Lipets I, Pritulo OA, Svyatenko TV, Andrashko Y, Lebwohl M, Gottlieb A. Pilot, multicenter, double-blind, randomized placebo-controlled bilateral comparative study of a combination of calcipotriene and nicotinamide for the treatment of psoriasis. J Am Acad Dermatol 2010;63(5):775-81. 339. Uliasz A, Lebwohl M. Evaluation of sensory irritation caused by topical medications using a novel technique. Int J. Dermatol 2010;49(3):269-71. 340. Koutruba N, Emer J, Lebwohl M. Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis. Ther Clin Risk Manag 2010;6:123-41. 341. Zeichner JA, Lebwohl MG, Menter A, Bagel J, Del Rosso JQ, Elewski BE, Feldman SR, Kircik LH, Koo J, Gold LS, Tanghetti E for the Psoriasis Process of Care Consensus Panel. Optimizing topical therapies for treating posriasis: A consensus conference. Cutis 2010;86(3S):5-31. 342. Hadi SM, Al-Quran H, de Sá Earp AP, Hadi AS, Lebwohl M. The use of the 308-nm excimer laser for the treatment of psoriasis. Photomed Laser Surg 2010;28(5):693-5. 343. Lebwohl M, Yeilding N, Szapary P, Wang Y, Li S, Zhu Y, Reich K, Langley RG, Papp KA. Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations. J Am Acad Dermatol 201063(4):571-9. 344. Stern DK, Creasey AA, Quijije J, Lebwohl MG. UV-A and UV-B Penetration of 45 Normal Human Cadaveric Fingernail Plate. Arch Dermatol 2010 Dec 20. [Epub ahead of print] 345. Jorizzo JL, Markowitz O, Lebwohl MG, Bourcier M, Kulp J, Meng TC, Levy S. A randomized double-blinded, placebo-controlled, multicenter, efficacy and safety study of 3.7% imiquimod cream following cryosurgery for the treatment of actinic keratoses. J Drugs Dermatol 2010;9(9):1101-8. 346. Lebwohl M. Tumour necrosis factor-α blockers in the treatment of psoriasis. Br J Dermatol 2010;162(6):1169-71. doi: 10.1111/j.1365-2133.2010.09835.x. [Epub ahead of print] 347. Barker J, Horn E, Lebwohl M, Warren R, Nast A, Rosenberg W, Smith C; on behalf of the International Psoriasis Council. Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic. J Eur Acad Dermatol Venereol 2010;29. doi: 10.1111/j.1468-3083.2010.03932.x. [Epub ahead of print] 348. Reich K, Langley RG, Lebwohl M, Szapary P, Guzzo C, Yeilding N, Li S, Hsu MC, Griffiths CE. Cardiovascular safety of ustebiinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. Br J Dermatol 2011;164(4):862-72. 348. Lolis MS, Krishtul A, Vidal C, Shim-Chang H, Phelps R, Lebwohl M. Necrolytic migratory erythema associated with a metastatic neuroendocrine tumor. Cutis 2011;87(2):78-80. 349. Emer JJ, Frankel A, Sohn A, Lebwohl M. A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of ammonium lactate lotion 12% and halobetasol propionate ointment in the treatment and maintenance of psoriasis. J Clin Aesthet Dermatol 2011;4(2):2839. 350. Grozdev IS, Van Voorhees AS, Gottlieb AB, Hsu S, Lebwohl MG, Bebo BF Jr, Korman NJ; for the National Psoriasis Foundation. Psoriasis in the elderly: From the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2011 Apr 13. [Epub ahead of print] 351. Yoo JY, Blum RR, Singer GK, Stern DK, Emanuel PO, Fuchs W, Phelps RG, Terry SF, Lebwohl MG. A randomized controlled trial of oral phosphate binders in the treatment of pseudoxanthoma elasticum. J Am Acad Dermatol 2011 Apr 13 [Epub ahead of print] 352. Frankel A, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl M, Bebo BF Jr, Gottlieb A. In response to “Treatment of psoriasis with cyclosporine in patients with hepatitis C infection: Risk or opportunity. J Am Acad Dermatol. 2011;64(4):788-90. 353. Kalb RE, Strober B, Weinstein G, Lebwohl M. Methotrexate and psoriasis: Consensus 46 conference. J Am Acad Dermatol 2011;64(6):1179. 354. van de Kerkhof P, Kragballe K, Segaert S, Lebwohl M; International Psoriasis Council. Factors impacting the combination of topical corticosteroid therapies for psoriasis: perspectives from the international psorisis council. J Eur Acad Dermatol Venereol. 2011 May 13. doi: 10.1111/j.14683083.2011.04113.x.[Epub ahead of print] Boo k Chapters: Chapters 1. Fleischmajer R, Lebwohl M: The pathogenesis of scleroderma in The Pathogenesis of Skin Diseases. (B Theirs, R Dobson, eds), Churchill Livingstone, New York, NY pp 233-247, 1986. 2. Fleischmajer R, Lebwohl M: Cutaneous lesions in connective tissue diseases in Difficult Diagnoses in Dermatology. (M Lebwohl, ed), Churchill Livingstone, New York, NY pp 31-44, 1988. 3. Fleischmajer R, Lebwohl M: Systemic sclerosis, (scleroderma) and pseudoscleroderma in Difficult Diagnoses in Dermatology. (M Lebwohl, ed), Churchill Livingstone, New York, NY pp 11-30, 1988. 4. Lebwohl M: Neonatal bullous diseases in Difficult Diagnoses in Dermatology. (M Lebwohl, ed), Churchill Livingstone, New York, NY pp 221-240, 1988. 5. Phototherapy and Photochemotherapy in Dermatologic Practice (Symposium Proceedings) M Lebwohl, Program Chairman. New York, NY, Mount Sinai School of Medicine, 1992. 6. Lebwohl M: Alternative therapies for psoriasis in Current Opinion in Dermatology (M Dahl, P Lynch, eds), Current Science, Philadelphia, PA pp 3-9, 1994. 7. Hecker D, Lebwohl M: Pustular psoriasis. Pearls and Pitfalls in Dermatology (T Habif, ed) Greenwich Press, Connecticut pp 5-8, 1995. 8. Simon A, Lebwohl M: Cowden’s disease. Pearls and Pitfalls in Dermatology (T Habif, ed) Greenwich Press, Connecticut pp 57-60, 1995. 9. Lebwohl M, Baral J: Pseudoxanthoma elasticum. Pearls and Pitfalls in Dermatology (T Habif, ed) Greenwich Press, Connecticut pp 81-84, 1995. 10. Lebwohl M: Future psoriasis therapy in Psoriasis (M Lebwohl, M Zanolli, eds), Dermatologic Clinics of North America. W. B. Saunders Company, Philadelphia, PA pp 915-923. 11. DeLauro TM, Lebwohl M: Dermatologic manifestations of systemic disease in Clinics in Podiatric Medicine and Surgery (K Ward, guest ed), W. B. Saunders Company, Philadelphia, PA 15(3):389-409, 1998. 47 12. Tan MH, Lebwohl M: Severe, recalcitrant psoriasis in a 28-year-old woman in Medical Simulations in the Management of Severe Psoriasis, InterMed Press, Darien, CT, pp 4-11, 1999. 13. Lebwohl M: Acne and related disorders in Scientific American Medicine (DC Dale and DD Federman, eds), Scientific American, Inc., New York, NY 1999. 14. Lebwohl M: Cutaneous manifestations of systemic disease in Scientific American Medicine (DC Dale and DD Federman, eds), Scientific American, Inc., New York, NY 1999. 15. Lebwohl M, Hecker D: Combination therapy: Calcipotriene and corticosteroids in Vitamin D in Dermatology (K Kragballe, ed), Marcel Dekker, Inc., New York, NY 16. Lebwohl M: Advances in psoriasis therapy in New and Emerging Therapies (BH Theirs, ed), W. B. Saunders Company, Philadelphia, PA, 18(1):13-19, 2000. 17. Lebwohl M: Pseudoxanthoma elasticum in Textbook of Pediatric Dermatology (J Harper, A Oranje, N Prose, eds), Blackwell Science, London, UK 2:1277-1285, 2000. 18. Fuchs WS, Lebwohl MG: The ocular manifestations of pseudoxanthoma elasticum in Vision Rehabilitation: Assessment, Intervention and Outcomes (C Stuen, A Arditi, A Horowitz, MA Lang, B Rosenthal, KR Seidman, eds), Swets & Zeitlinger, Lisse, 2000. 19. Lebwohl M, Gelfand J: Clinically significant therapeutic interactions for the practicing dermatologist in Advances in Dermatology Vol. 14 (in press). 20. Lebwohl M: Acquired perforating disorders in Fitzpatrick’s Dermatology in General Medicine 6th edition (IM Freedberg, AZ Eisen, K Wolff, KF Austen, LA Goldsmith, SI Katz, eds), McGraw Hill, New York, NY pp 1041-1045 - 2003. 21. Berman B, De Araujo T, Lebwohl M: Immunomodulators in Dermatology (JL Bolognia, JL Jorizzo, RP Papini, eds), Harcourt Health Science, London, UK pp 2033-2054, 2003. 22. Gohara M, Lebwohl M: Pyoderma gangrenosum in The NORD Guide to Rare Diseases, Lippincott, Williams & Wilkins, pp 134-135, 2003. 23. Sherer D, Lebwohl M. Pseudoxanthoma Elasticum in The NORD Guide to Rare Diseases, Lippincott, Williams & Wilkins, pp 133-134, 2003. 24. Lebwohl M. Combination, Rotational, and Sequential Therapy in Therapy of Moderate to Severe Psoriasis, (GD Weinstein, AB Gottlieb, eds), Marcel Dekker, Inc. New York, NY 1:179-195, 2003. 25. Lebwohl M. Cutaneous Manifestations of Systemic Disease in Scientific American Medicine (David C. Dale, Daniel D. Federman, eds) WebMD, New York, pp 393-404, 2003. 26. Lebwohl M. Acne Vulgaris and Related Disorders in Scientific American Medicine (David C. Dale, Daniel D. Federman, eds), WebMD, New York, pp 405-410, 2003. 48 27. Abel EA, Lebwohl M. Psoriasis in Scientific American Medicine (David C. Dale, Daniel D. Federman, eds), WebMD, New York, pp 419-429, 2003. 28. Aaronson DS, Lebwohl M. Review of Therapy of Psoriasis: The Prebiologic Armamentarium in Dermatologic Clinics ( Bruce H. Thiers, consulting ed, Alan Menter, Jennifer Cather, guest eds), Saunders Philadelphia; 22(4):379-388, 2004. 29. Gritsenko K, Gordon M, Lebwohl M. Genetic Disorders Predisposing to Cutaneous Malignancy in Cancer of the Skin (Darrell S. Rigel, Robert J Friedman, Leonard M Dzubow, Douglas S. Reintgen, Jean-Claude Bystryn, Robin Marks, eds), Elsevier Saunders, Philadelphia, p. 363-370, 2004. 30. Berkowitz E, Lebwohl M. Cutaneous Carcinogenesis Related to Dermatologic Therapy in Cancer of the Skin (Darrell S. Rigel, Robert J Friedman, Leonard M Dzubow, Douglas S. Reintgen, Jean-Claude 2004. 31. Lebwohl M. Cutaneous Manifestations of Systemic Disease in ACP Medicine (David C. Dale, Daniel D. Federman, eds) WebMD, New York, p. 393-404, 2005. 32. Lebwohl M. Acne Vulgaris and Related Disorders in ACP Medicine (David C. Dale, Daniel D. Federman, eds), WebMD, New York, p. 405-410, 2005. 33. Abel EA, Lebwohl M. Psoriasis in ACP Medicine (David C. Dale, Daniel D. Federman, eds), WebMD, New York, p. 419-429, 2005. 34. Stern DK, Tripp JM, Ho VC, Lebwohl M. The Use of Systemic Immune Moderators in Dermatology: An Update in Dermatologic Clinics (Bruce H. Thiers, consulting ed, David I Mclean, W. Stuart Maddin, guest eds), Saunders Philadelphia; 23(2):259-300, 2005. 35. Soung J, Lebwohl M. Clinical Presentation of Psoriasis in Psoriasis and Psoriatic Arthritis: An Integrated Approach (Kenneth B. Gordon; Eric M. Ruderman, eds), Springer, 258 p., 2005. 36. Lebwohl M, Pseudoxanthoma Elasticum in Textbook of Pediatric Dermatology (John Harper; A Oranje; N Prose, eds), Blackwell Publishing Ltd, (2nd edition), Massachusetts, Vol. 2, 16631670, 2006. 37. Stern DK, Lebwohl M, Papulosquamous Eruptions in Conn’s Current Therapy 2006 (Robert E. Rakel; Edward T. Bope, eds), Saunders, Philadelphia, PA, 962-970, 2006. 38. Lebwohl MG. Introduction in Mild-to-Moderate Psoriasis 2006 (John YM Koo, Mark G. Lebwohl, Chai Sue Lee eds.) Informa Healthcare, New York, NY1-2, 2006. 39. Koo JYM, Kowalski JW, Lebwohl MG, Kozma CM, Menter A.. The Koo- Menter Psoriasis Instrument for Identifying Candiate Patients for Systemic Therapy in Mild-to-Moderate Psoriasis 2006 (John YM Koo, Mark G. Lebwohl, Chai Sue Lee eds.) Informa Healthcare, New York, NY1-2, 2006. 49 40. Tinio P, Lebwohl MG. Topical Calcineurin Inhibitors in Mild-to-Moderate Psoriasis 2006 (John YM Koo, Mark G. Lebwohl, Chai Sue Lee eds.) Informa Healthcare, New York, NY1-2, 2006. 41. Diamantis S, Lebwohl M. Dermatologic Management of Psoriasis in Psoriatic and Reactive Arthritis: A Companion to Rheumatology (Christopher T. Ritchlin, Oliver Fitzgerald, eds), Elsevier, Philadelphia, PA, 42 Lebwohl MG. Other Topical Medications in Dermatology 2nd edition (Jean L. Bolognia, Joseph L. Jorizzo, and Ronald P. Rapini et al., eds) Elsevier, London 43 Lebwohl M, Hecker DJ. Combination Therapy: Calcipotriol and Cortico-steroids in Vitamin D in Dermatology (Knud Kragballe, ed) Marcel Dekker, Inc. New York 44. Palep SR, Lebwohl MG. T-Cell Activation Inhibitorrs: Alefacept and Efalilzumab in Comprehensive Dermatologic Drug Therapy 2nd edition (Stephen E. Wolverton, ed) Saunders, Philadelphia, PA 45. Lebwohl M. Acquired Perforating Disorders in Fitzpatrick’s Dermatology in General Medicine 7th edition 2007 ( Klaus Wolff, Lowell A. Goldsmith, Stephen I. Katz, Barbara A. Gilchrest, Amy S. Paller, David J. Leffell, eds) McGraw Hill Medical, New York. 46… Landry CA, Lebwohl M. Topical Calcineurin Inhibitors in Mild to Moderate Psoriasis, (John YM Koo, Mark G. Lebwohl, Chai S. Lee, eds) 2nd edition, 2008. 47. Uliasz A, Lebwohl M. Topical Immune Response Modifiers: Adjuvants in Clinical and Basic Immunodermatology (Anthony A. Gaspari, Stephen K. Tyring, eds). Springer, London, 2008. 48. Gerstner GL, Lebwohl MG. Alopecia Mucinosa. eMedicine from WebMD. Updated January 22, 2009. Available at http://www.emedicine.com/derm/topic15.htm. 49. Al-Hammadi A, Lebwohl MG. Nevus Sebaceus. e-medicine from WebMD. Updated October 23, 2009. `http://emedicine.medscape.com/article/1070090-overview 50. Lebwohl M. Foreward in Psoriasis: Optimizing Therapeutic Response Hasmukh Shroff, Hemangi Jerajani, Shehnaz Arsiwala, Meghana Phiske, eds. Bhalani Publishing House, Mumbai, India, 2010. Invited Articles and Other Publications 1. Lebwohl M, DiStefano D, Prioleau P, Uram M, Yannuzzi L, Fleischmajer R: Pseudoxanthoma elasticum and mitral valve prolapse. N Engl J Med. 1982; 307:1452. 2. Lebwohl M, Berman B: The major cutaneous signs of internal malignancy: Spotting them sooner. Modern Med. 1983;51:96-110. 3. Lebwohl M: Cutaneous manifestations of internal malignancy. J Family Med. 1983; 8-16. 4. Lebwohl M: New advances in the treatment of psoriasis. J Family Med. 1983; December 11-9, 50 5. Lebwohl M: Photoimmunology. Int J Dermatol. 1984;23:632. 6. Rubenstein AE, Seitz SC, Wallace S. Aron AM, Lebwohl M: Increased risk of congenital premalignant melanocytic nevi in neurofibromatosis. Neurology. 1985;35:194. 7. Lebwohl M: Porphyria. J Dermatologic Surg Oncol. 1986;12:6. 8. Lebwohl M: Pseudoxanthoma elasticum. J Am Acad Dermatol. 1989;20:311. 9. Lebwohl M: Staphylococcus aureus: Dermatologic infections in the young adult patient. Modern Med. 1989;57(Suppl. A):44-8. 10. Lebwohl M: Topical tipredane in the treatment of psoriasis and atopic dermatitis. Syllabus of the Fourteenth Hawaii Dermatology Seminar, 1990. 11. Katz HI, Koo J, Krueger GG, Lebwohl MG, Shelley ED: Waging war on psoriasis. Patient Care. 1992;26:145-75. 12. Lebwohl M: The skin and neurofibromatosis 1. Neurofibromatosis (J Nat’l Neurofibromatosis Foundation), 1992;133:2,7. 13. Bruckner H, Gorbaty M, Lipsztein R, Kranjac G, Lebwohl M: Treatment of a large high-grade neurofibrosarcoma with concomitant vinblastine, doxorubicin, and radiotherapy. Mt Sinai J Med. 1992;59:429-32. 14. Lebwohl M: Differential diagnosis of pigmented lesions of the skin. Mt Sinai J Med. 1992;59:194-7. 15. Lebwohl M: Therapy for psoriasis – overview. Syllabus of Symposium on Phototherapy and Photochemistry in Dermatologic Practice. Department of Dermatology, The Page and William Black Post-Graduate School, The Mount Sinai School of Medicine, May 1992. 16. Lebwohl M: Principles of phototherapy. Syllabus of Symposium on Phototherapy and Photochemistry in Dermatologic Practice. Department of Dermatology, The Page and William Black Post-Graduate School, The Mount Sinai School of Medicine, May 1992. 17. Lebwohl M: Pseudoxanthoma elasticum. New Engl J Med. 1993;329:1240. 18. Lebwohl M: Calcipotriol: A new class of topical treatment. Fitzpatrick’s J Clin Dermatol. 1993;1:35. 19. Davis K, Lebwohl M, Bottone EJ: Sterility of refrigerated injectable collagen syringes. J Am Acad Dermatol. 1993;29:507-8. 20. Lebwohl M: An end to diets for psoriasis? Fitzpatrick’s J Clin Dermatol. 1994;42-3. 21. Lebwohl M, Phelps R, Halperin J: Pseudoxanthoma elasticum. N Engl J Med. 1994;330:793. 51 22. Bruer JN, Lebwohl M: Pseudoxanthoma elasticum. PXE Awareness. 1994; 2:1,3. 23. Bruder J, Lebwohl M: Analysis: Bacon therapy of furuncular myiasis. Fitzpatrick’s J Clin Dermatol. 1994; March/Apr 32. 24. Hecker DJ, Lebwohl M: Acyclovir-resistant herpes simplex. Fitzpatrick’s J Clin Dermatol May/June pp 29-30, 1994. 25. Dubin DB, Duncan LM, Lebwohl M: Hidden dermatopathology. Fitzpatrick’s J Clin Dermatol September/October pp 10-23, 1994. 26. Lebwohl M: Calcipotriene for scalp psoriasis. Fitzpatrick’s J ClinDermatol November/December p 66, 1994. 27. Simon AE, Lebwohl M: On the trail of a psoriasis gene. Fitzpatrick’s J Clin Dermatol November/December p 66, 1994. 28. Gerardi C, Lebwohl M: Case 1-1994: Pseudoxanthoma elasticum Mt Sinai J Med. 1995;62:60-1. 29. Simon AE, Lebwohl M: Psoralen bath and UVA for psoriasis. Fitzpatrick’s J Clin Dermatol 3(1):26-30, 1995. 30. Gerardi CM, Kahn H, Case 2-1995 from Weekly Grand Rounds, Department of Dermatology, Mount Sinai Hospital (M Lebwohl, ed) Mt Sinai J Med. 1995;62(3):243-4. 31. Lebwohl M: Psoriasis. Arch Dermatol. 1995;131:500. 32. Khorenian SD, Lebwohl M: New cutaneous manifestations of systemic disease. Am Fam Physician. 1995;51(3):625-30. 33. Lebwohl M: Pitfalls in the use of calcipotriene. Psoriasis Forum. 1995;2:1-2. 34. Sapadin A, Lebwohl M: White fibrous papulosis. Mt Sinai J Med. 1995; 62(4):315. 35. Lebwohl M, Baral J: Tar melanosis. Mt Sinai J Med. 1995;62:412. 36. Rudikoff D, Lebwohl M: Psoriatic arthritis. Mt Sinai J Med. 1995;62:453. 37. Simon AE, Lebwohl M: Psoriatic arthritis. Fitzpatrick’s J Clin Dermatol September/October p 33, 1995. 38. Yoles A, Lebwohl M: Psoriasis as an immunologic disease. Fitzpatrick’s J Clin Dermatol 3(6):65-66, 1995. 39. Lebwohl M: Dermatological signs of internal disease (2nd edition). J Am Acad Dermatol 1995;114:526. 52 40. Yoles A, Lebwohl M: New developments and controversies in the use of methotrexate. Psoriasis Forum. 1995;1(3):3-4. 41. Lebwohl M: Management of psoriasis during pregnancy. Psoriasis Forum. 1995;1(3):3-4. 42. Gordon M, Lebwohl M: Vitiligo. Mt Sinai J Med. 1996;63:134. 43. National Psoriasis Foundation Consensus Conference: Proceedings of the psoriasis combination & rotation therapy conference. J Am Acad Dermatol. 1996;34:315-21. 44. Rudikoff D, Lebwohl M: Genital Herpes. Mt Sinai J Med. 1996;63:428. 45. Nichols K, Berkowitz E, Lebwohl M: Are there topical corticosteroids with improved benefit-torisk ratio? Psoriasis Forum. 1996;2(4):1-2. 46. Lebwohl M: Nail psoriasis. The Bulletin (National Psoriasis Foundation). 1996; 27:8-9. 47. Hecker D, Lebwohl M: Palm and sole psoriasis. Psoriasis Forum. 1996;2(1):1-2. 48. Truter S, Rosenbaum-Fiedler J, Sapadin A, Lebwohl M: Calcification of elastic fibers in pseudoxanthoma elasticum. Mt Sinai J Med. 1996;63:210-15. 49. Patient Presentation, 1997 Summer Session, American Academy of Dermatology, Book of Case Reports. M Lebwohl, D Frankel, C Gropper, P. Halperin, T Laude, M Reichel, R Scher, R Phelps, eds. 50. Schultz N, Lebwohl M: Cushing’s syndrome Mt Sinai J Med. 1997;64(2):146. 51. Lebwohl M: The 10 most common mistakes in the topical treatment of psoriasis. Psoriasis Forum 3(2):4, 1997. 52. Putman S, Lebwohl M: Safe and effective treatments available for genital psoriasis. The Bulletin of the National Psoriasis Foundation 28(2):6-7, 1997. 53. Lebwohl M: The ten most common errors in the topical treatment of psoriasis. National Psoriasis Foundation Pharmacy News 9:1-2, 1997. 54. Baral J, Lebwohl M: Tacalcitol, A viewpoint. Drugs. 1997;54(2):272. 55. Lebwohl M: The future of Skin-Cap. The Schoch Letter. 1997;47(9):1. 56. Putnam S, Lebwohl M: Treatment of genital psoriasis. Psoriasis Forum 3(1):4-5, 1997. 57. Lebwohl M, Kurtin S: Lyme disease. Mt Sinai J Med. 1997;64(6):418. 58. Lebwohl M: Understanding psoriasis. Women’s Health Digest. 1997;3(3):159-64. 53 59. Hecker MS, Hecker D, Lebwohl M: Pyoderma gangrenosum. Book of Case Reports. Patient Presentations, 1997 Summer Session, American Academy of Dermatology. 60. Wei H, Lebwohl M: Sarcoid. Book of Case Reports. Patient Presentations, 1997 Summer Session, American Academy of Dermatology. 61. Sapadin A, Bercovitch L, Lebwohl M: Pseudoxanthoma elasticum. Book of Case Reports. Patient Presentations, 1997 Summer Session, American Academy of Dermatology. 62. Ali S, Lebwohl M: Necrobiosis lipoidica diabeticorum. Book of Case Reports. Patient Presentations, 1997 Summer Session, American Academy of Dermatology. 63. Solganick J, Tan M-H, Lebwohl M: Adverse effects of systemic treatments: Methotrexate. Psoriasis Forum 3(4):4-5, 1997. 64. Tan M-H, Solganick J, Lebwohl M: Adverse effects of systemic psoriasis treatments: Retinoids. Psoriasis Forum 3(4):6-7, 1997. 65. Lebwohl M: Treatment of psoriasis of the face and other sensitive areas. Psoriasis-Therapeutic Dilemmas and Solutions, 6th Congress of the European Academy of Dermatology and Venereology pp 12-17, 1997. 66. Shelton R, Lebwohl M: Risks of HIV infection. Mt Sinai J Med. 1998;65:40. 67. Lebwohl M, Tan M-H: Psoriasis and stress. Lancet. 1998;351(9096):82. 68. Lebwohl M, Kurtin S: Reactive perforating collagenosis. Mt Sinai J Med. 1998;65(2):158. 69. Solganick J, Tan M-H, Lebwohl M: Adverse effects of systemic treatments: Cyclosporine. Psoriasis Forum 4(1):5, 1998. 70. Lowenstein E, Lebwohl M: Segmental neurofibromatosis. Book of Case Reports, 75th Atlantic Dermatological Conference, May 1998. 71. Rahimizadeh A, Wei H, Lebwohl M: Cowden’s syndrome. Book of Case Reports, 75th Atlantic Dermatological Conference, May 1998. 72. Hecker D, Hecker M, Lebwohl M: Pyoderma gangrenosum. Book of Case Reports, 75th Atlantic Dermatological Conference, May 1998. 73. Fiedler J, Lebwohl M: Basal cell carcinoma treated by photodynamic therapy. 70. Book of Case Reports, 75th Atlantic Dermatological Conference, May 1998. 74. Hecker DJ, Hecker MS, Lebwohl M: Photographing psoriasis. MD Photoderm. 1998;1(1):3-5. 75. Meara S, Lebwohl M: Management of erythrodermic psoriasis. Psoriasis Forum. 1998;4(2):1-2. 54 76. Gottlieb A, Krueger J, Bright R, Ling M, Lebwohl M, Kang W, Feldman S, Spellman M, Miller L, Ochs H, Dedrick R, Garovoy M: Phase I trial of psoriasis with an anti-CD11a (LFA-1) monoclonal antibody (mAb) (Poster 1243). Int Soc Invest Dermatol May 3-7, 1998. 77. Gordon M, Lebwohl M: Generalized morphea. Mt Sinai J Med. 1998;65(4):308. 78. Baral J, Lebwohl M: Cirrhosis. Mt Sinai J Med. 1998;66(1):37. 79. Gordon M, Lebwohl M: Actinic reticuloid. Mt Sinai J Med. 1998;66(2):133. 80. Meador S, Tan M-T, Lebwohl M: Case profile. Psoriasis Forum. 1998;4(4):1-2. 81. Sherer D, Lebwohl M: Mycophenolate mofetil for psoriasis. Psoriasis Forum 4(4):6, 1998. 82. Lebwohl M: Review of Handbook of Psoriasis by C Camisa, Blackwell Science Inc., Molden, MA, 1998. Arch Dermatol 135:220, 1999. 83. Lebwohl M, Baral J: Combination therapy: retinoids and ultraviolet light. Psoriasis Forum 5(1):1-2, 1999. 84. Buka R, Gordon M, Lebwohl M. How to use retinoids to prevent skin cancer and treat photoaging. First Annual Photoaging & Skin Issue; June 1999. 85. Carlin CS, Parker JF, Callis KP, Klein SZ, Wong B, Grummer S, Feldman S, Persaud A, Lebwohl M, Krueger GG. The National Psoriasis Foundation Psoriasis Score – an alternative tool to the Psoriasis Area and Severity Index in the evaluation of psoriasis in clinical trials. Psoriasis Forum. Winter 1999. 86. Rudikoff D, Baral J, Lebwohl M: Psoriasis and Crohn’s disease. Mt Sinai J Med. 1999;66(3):206. 87. Rigel R, Lebwohl M, Thiers B, Feldman S: Cutting-edge advice to improve clinical care. Skin & Aging 8-15, May 1999. 88. Lebwohl M: How to improve clinical outcomes of psoriasis therapy. Skin Aging 16-21, May 1999. 89. Koo J, Lebwohl M: Cyclosporine-associated lymphoma. J Am Acad Dermatol. 1999;40(6):1016. 90. Lebwohl M: Vitamin E (α-tocopherol), 800 IU daily, may reduce retinoid toxicity. J Am Acad Dermatol. 1999;41:260. 91. Lefkovits AM, Gordon M, Lebwohl M: Erythema nodosum Mt Sinai J Med. 1999;66(4):290. 92. Lebwohl M: Recent advances in drug therapy for psoriasis. J Watch Dermatol. 1999;7(11):94. 93. Baral J, Lebwohl M: Extramammary Paget’s disease. Mt Sinai J Med. 1999;66(5-6):341. 55 94. Hobbs J, Lebwohl M, Lim HW: Improving the safety profile of long term PUVA therapy. J Am Acad Dermatol. 1999;41 (3 Pt 1):496-7. 95. Sherer DW, Sapadin AN, Lebwohl MG: Pseudoxanthoma elasticum: an update. Dermatology. 1999;199(1):3-7. 96. Wei H, Sapadin AN, Buka R, Mauch J, Freund B, Lebwohl M, Rudikoff D: Pseudoxanthoma elasticum with calcinosis cutis. Book of Case Reports. Patient Presentations 1999, Summer Session, American Academy of Dermatology. 97. Smith KC, Lebwohl M: Topical antipsoriatics. Skin Therapy Letter. 2000;5(2):1-2. 98. Lebwohl M: 12 psoriasis treatment pearls that really do work. Skin & Aging 10-15, February 2000. 99. Lefkovits AM, Lebwohl MG: Vitamin K reaction. Mt Sinai J Med. 2000;6(2):172. 100. Lebwohl M. Odom R, James W, Berger T. Review of Andrews’ Diseases of the Skin: Clinical Dermatology, 9th Edition, W. B. Saunders Company, Philadelphia PA, Clin Dermatol 19:00-00, 2001. (in press). 101. Rudikoff D, Lebwohl M: AIDS-related Kaposi’s sarcoma. Mt Sinai J Med. 2001;68(1):13. 102. Baral J, Lebwohl MG: Thermal burn. Mt Sinai J Med. 2001;68(3):226. 103. Lebwohl M: Eflornithine hydrochloride cream effective in the reduction of unwanted facial hair in women. Scientific American Med Bull 24:6, 2001. 104. Lebwohl M: Introduction: Dermatology Theme Issue, Mt Sinai J Med. 2001;68(4&5):230-31. 105. Stein RH, Lebwohl M: Acne therapy. Seminars in Cutaneous Med Surg. 2001;20(3):184-9. 106. Krupnick A, Lebwohl M: Seborrheic dermatitis. Photo & Derm. 2001;4(1):11-4. 107. Singh F, Lebwohl M: Etanercept: Dosing, monitoring and side effects. Psoriasis Forum Winter 2002, p 10. 108. Lebwohl MG, Feldman SR, Koo JYM, Menter A. Psoriasis: Treatment Options and Patient Management. National Psoraisis Foundation. Portland, OR pp 102, 2002. 109. Akhavan A, Lebwohl M. Systemic psoriasis treatment with alefacept. Psoriasis Forum Spring 2003, pp 4,5. 110. Moore JO, Saladi RN, Shultz NB, Lebwohl MG, Phelps RG. Epidermotropic metastatic malignant melanoma (EMMM) – a pathological variant of melanoma. J Am Osteopath Coll Dermatol 1(1): 68-70, 2003. 56 111. Ku S, Lebwohl M. “Classification of psoriasis by its natural history” Psoriasis Forum, Spring 2003. 112. Lebwohl MG. Biologic therapies for psoriasis. What’s New in ACP Medicine. 2004;27 (8):1-2. 113. Lebwohl M. Psoriasis update: Today’s topical treatment strategies to optimize patient response and quality of life. Dermatology Times, June 2004. 114. Lebwohl M: Review of Handbook of Psoriasis. Arch Dermatol (accepted) 115. Persaud AN, Lebwohl M: Psoriasis. Current Practice of Medicine 2000 (in press) 116. Green JB, Lebwohl M: Interactions of common psoriasis treatments. Psoriasis Forum (in press). 117. Lebwohl MG: The potential of TNF inhibitors relative to other therapies. Skin & Allergy News (in press). 118. Lebwohl M: Foreward to Handbook of Psoriasis 2nd Edition (C Camisa, ed.) Blackwell Publishing, Ltd, Malden, MA, pp 368, 2004 (invited) 119. Feldman SR, Koo JYM, Lebwohl MG, Menter A, Van Voorhees A. Psoriasis and Psoriatic Arthritis Pocket Guide: Treatment Algorithms and Management Options. National Psoraisis Foundation. Portland, OR pp 139, 2005. 120. Lebwohl M. Avoiding Pitfalls in the Treatment of Psoriasis. Skin & Aging. 2005;(Suppl), 7-10. 121. Lebwohl M. Changes in the treatment of psoriasis and psoriatic arthritis. ACP Medicine 2006; 29(9):1-3. 122. Lebwohl M. A safety assessment of topical calcineurin inhibitors in the treatment of atopic dermatitis. www.medgenmed.com. October 2006. 123. Lebwohl M. Advances in systemic psoriasis therapy benefit other immune-mediated diseases. ACP Medicine –Practice of Medicine, September 2007. 124. Lebwohl M, Wong VK, Della Croce C. Expanding the therapeutic options for psoriatic conditions. Patient Care Allergy & Immunology August 2007; 6-12. 125. Lebwohl M. Psoriasis drugs for patients without psoriasis. ACP Medicine 2007; 30(12):1-2. 126. Lebwohl M. Forward in Handbook of Psoriasis 2nd edition, (Charles Camisa ed), Blackwell Publishing.Malden, Massachusetts, 2004 127. Lebwohl M. Forward in Obstetric Dermatology, Arieh Ingber, Springer-Verlag. Berlin, 2009. 128. Colpi L, Lebwohl MG. What’s new in psoriasis? Balancing the therapeutic scales. J Clin Aesthetic Dermatol. 2008; 2(41):12-5. 57 129. Lebwohl M. The changing face of skin cancer. ACPMedicine 2009;32(2):1-3. 130. Van Voorhees A, Feldman SR, Koo JYM, Lebwohl MG, Menter A. Psoriasis and Psoriatic Arthritis Pocket Guide: Treatment Algorithms and Management Options. National Psoraisis Foundation. Portland, OR pp 134, 2009. 131. Lebwohl MG, Gerstner GL, Alopecia mucinosa, eMedicine Specialties, updated Jan 22, 2009. 132. Lebwohl MG, Al-Hammadi A, Nevus sebaceus, eMedicine Specialties, updated Jun 9, 2010. 133. Foreword, Goodheart’s Same Site Differential Diagnoses Walters Kluwer Lippincott Williams & Wilkins (published), 2011 134. Foreword for Contemporary Diagnosis and Management of Psoriasis 5th edition, National Psoriasis Foundation, by John Koo, Tina Bhutani and Judith Hong, Handbooks in Health Care Company, 2011. 135. Lebwohl M. Biologic therapy of psoriasis: Progress and problems (Part 1). ACP Medicine 2011; 34(4):1-2. 136. Lebwohl M Commentary on Reduced melanoma after regular sunscreen use: randomized trial follow-up. Ann Int Med. ACP Journal Club. 2011 May 17;154:JC5-12. Abstracts 1. Lundin AP, Lebwohl M, Strom TB, Carpenter CB: Early role of cAMP in suppression of rat MLR. Clin Res 24:332A, 1976. 2. Lebwohl M, Fleischmajer R, Lovelace O, Timpl R: Immunofluorescent analysis of collagens, laminin, and fibronectin, and immunoelectron microscopy of fibronectin in pseudoxanthoma elasticum skin. Clin Res 32:597A, 1984. 3. Lebwohl M, Fleischmajer R, Lovelace O, Timpl R: Immunofluorescent analysis of collagens, laminin, and fibronectin, and immunoelectron microscopy of fibronectin in pseudoxanthoma elasticum skin. J Invest Dermatol 82:433, 1984. 4. Berman B, Silverstein L, Jaliman D, France D, Lebwohl M, Peets E, Tanner D, Taylor E: Effectiveness of interferon-alpha in the treatment of verruca vulgaris. Clin Res 32:254A, 1984. 5. Fleischmajer R, Timpl R, Lebwohl M: The extracellular matrix in neurofibromas. Clin Res 33:637A, 1985. 6. Longas MO, Wisch P, Lebwohl M: Skin and urine glycosaminoglycans in pseudoxanthoma elasticum. Clin Res 33:662A, 1985. 7. Lebwohl M, Lovelace O, Palaia M, Longas M, Fleischmajer R: Ultrastructural localization of hyaluronic acid (HA) in pseudoxanthoma elasticum (PXE) skin. Clin Res 33:661A, 1985. 58 8. Schwartz E, Lebwohl M, Fleischmajer R: Synthesis of elastic fiber components by human skin fibroblasts. Clin Res 33:681A, 1985. 9. Schwartz E, Lebwohl M, Fleischmajer R: Synthesis of elastic fiber components by human skin fibroblasts. J Invest Dermatol 84:318, 1985. 10. Schwartz E, Lebwohl M, Johnson D, Aviles M, Fleischmajer R: Determination of calcium (Ca) concentrations in epidermis, dermis and fat. Clin Res 33:681A, 1985. 11. Longas MO, Wisch P, Lebwohl M: Skin and urine glycosaminoglycans in pseudoxanthoma elasticum. J Invest Dermatol 84:318, 1985. 12. Fleischmajer R, Timpl R, Lebwohl M: The extracellular matrix in neurofibromas. J Invest Dermatol 84:352, 1985. 13. Lebwohl M, Phelps R, Lemlich G, Palaia M, Longas M: Hyaluronic acid and dermatan sulfate in lesional and nonlesional pseudoxanthoma elasticum skin. Clin Res 34:762A, 1986. 14. Lebwohl M, Phelps R, Lemlich G, Palaia M, Longas M: Hyaluronic acid and dermatan sulfate in lesional and nonlesional pseudoxanthoma elasticum skin. J Invest Dermatol 86:487, 1986. 15. Schwartz E, Lebwohl M: Elastase-like protease activity in skin fibroblasts derived from elastotic lesions. Clin Res 34:780A, 1986. 16. Schwartz E, Lebwohl M: Elastase-like protease activity in skin fibroblasts derived from elastotic lesions. J Invest Dermatol 86:506, 1986. 17. Lemlich G, Lebwohl M, Schwartz E: Quantification of fibronectin in human skin. Clin Res 34:763A, 1986 18. Lemlich G, Lebwohl M, Schwartz E: Quantification of fibronectin in human skin. J Invest Dermatol 86:488, 1996. 19. Alweiss G, Lemlich G, Lebwohl M, Schwartz E: Desmosine levels in elastic related skin disorders. Clin Res 35:666A, 1987. 20. Alweiss G, Lemlich G, Lebwohl M, Schwartz E: Desmosine levels in elastic related skin disorders. J Invest Dermatol 88:474, 1987. 21. Koreen R, Weinflash-Konstadt J, Grabowski G, Longas M, Toome B, Lemlich G, Lebwohl M: Quantitative evidence of increased hyaluronic acid and dermatan sulfate in lesional and nonlesional pseudoxanthoma elasticum skin. Clin Res 35:696A, 1987. 22. Koreen R, Weinflash-Konstadt J, Grabowski G, Longas M, Toome B, Lemlich G, Lebwohl M: Quantitative evidence of increased hyaluronic acid and dermatan sulfate in lesional and nonlesional pseudoxanthoma elasticum skin. J Invest Dermatol 88:500, 1987. 59 23. Lebwohl M, Gordon M, Conant M, Connor J, Douglas J, Eron L, Marlowe S, Mendelson J, Sacks S, Bradstreet P, Fedorczyk D, Trout JR, Plasse T: Recombinant alpha-2 interferon gel in the treatment of recurrent herpes genitalis. Clin Res 35:698A, 1987. 24. Lebwohl M, Gordon M, Conant M, Connor J, Douglas J, Eron L, Marlowe S, Mendelson J, Sacks S, Bradstreet P, Fedorczyk D, Trout JR, Plasse T: Recombinant alpha-2 interferon gel in the treatment of recurrent herpes genitalis. J Invest Dermatol 88:502, 1987. 25. Lemlich G, Lebwohl M, Schwartz E: Preparation of a specific antibody directed against human dermal elastin. Clin Res 35:699A, 1987. 26. Lemlich G, Lebwohl M, Schwartz E: Preparation of a specific antibody directed against human dermal elastin. J Invest Dermatol 88:503, 1987. 27. Phelps R, Schwartz E, Harpaz N, Gordon R, Lebwohl M: Mouse model of atypical fibroxanthoma. Clin Res 35:710A, 1987. 28. Phelps R, Schwartz E, Harpaz N, Gordon R, Lebwohl M: Mouse model of atypical fibroxanthoma. J Invest Dermatol 88:512, 1987. 29. Lebwohl M, Chen VL, Conant M, Connor J, Douglas J, Eron L, Marlowe S, Mendelson J, Sacks S, Bradstreet P, Fedorczyk D, Trout JR, Plasse T: Recombinant alpha-2 interferon gel in the treatment of recurrent herpes genitalis. J Clin Pharmacol 27:710, 1987. 30. Olsen D, Lebwohl M, Fazio M, Uitto J: Enhanced elastin gene expression in pseudoxanthoma elasticum fibroblast cultures as determined by elastin mRNA steady-state levels. Clin Res 36:378A, 1988. 31. Lebwohl M, Schwartz E, Lemlich G, Shaikh-Bahai F, Fleischmajer R: Analysis of dermal connective tissue components in pseudoxanthoma elasticum. Clin Res 36:666A, 1988. 32. Lebwohl M, Schwartz E, Lemlich G, Shaikh-Bahai F, Fleischmajer R: Analysis of dermal connective tissue components in pseudoxanthoma elasticum. J Invest Dermatol 90:580, 1988. 33. Phelps R, Bloom L, Schwartz E, Gordon R, Lebwohl M: Ultraviolet light induced mouse dermal neoplasia. Clin Res 36:684A, 1988. 34. Phelps R, Bloom L, Schwartz E, Gordon R, Lebwohl M: Ultraviolet light induced mouse dermal neoplasia. J Invest Dermatol 90:598, 1988. 35. Lebwohl M, Rex IH, Tchen E, Tharp MD, Ward WQ, Whitmore C: Oxiconazole nitrate cream, 1% once or twice daily in the treatment of tinea pedis. Clin Res 37:662A, 1989. 36. Lebwohl M, Rex IH, Tchen E, Tharp MD, Ward WQ, Whitmore C: Oxiconazole nitrate cream, 1% once or twice daily in the treatment of tinea pedis. J Invest Dermatol 92:468, 1989. 37. Schwartz E, Cruickshank FA, Lebwohl M: Quantification of elastin and its desmosine residues in elastin-related disorders. Clin Res 37:672A, 1989. 60 38. Schwartz E, Cruickshank FA, Lebwohl M: Quantification of elastin and its desmosine residues in elastin-related disorders. J Invest Dermatol 92:515, 1989. 39. Schwartz E, Cruickshank FA, Lebwohl M: Quantification of elastin and its desmosine residues in elastin-related disorders. J Invest Dermatol 92:515, 1989. 40. Thieberg M, Lebwohl M, Lemlich G, Schwartz E: Enzymatic digestion of insoluble elastin from normal and pseudoxanthoma elasticum lesional skins. J Invest Dermatol 92:532, 1989. 41. Dunaif A, Green G, Levy L, Phelps R, Futterweit W, Lebwohl M: The significance of acanthosis nigricans (AN) in relationship to in vivo insulin action and hyperandrogenism. Annual Meeting American Diabetes Association 38:201A, 1989. 42. Gordon M, Lebwohl M, Phelps R, Cohen S, Fleischmajer R: L-tryptophan ingestion associated with eosinophilic fasciitis. Clin Res 38:625A, 1990. 43. Gordon M, Lebwohl M, Phelps R, Cohen S, Fleischmajer R: L-tryptophan ingestion associated with eosinophilic fasciitis. J Invest Derm 94:530, 1990. 44. Lebwohl M, Bottone E, Gordon M, Lucas D: Contamination of injectable bovine collagen needle tips with propionibacterium acnes. Clin Res 38:626A, 1990. 45. Lebwohl M, Bottone E, Gordon M, Lucas D: Contamination of injectable bovine collagen needle tips with propionibacterium acnes. J Invest Dermatol 94:547, 1990. 46. Lebwohl M, Phelps R, Gordon M, Fleischmajer R. Diseases of the dermis. J Am Acad Dermatol 23(2 Pt 1):295-299, 1990. 47. Fishman SJ, Phelps R, Fleischmajer R, Lebwohl M, Fisher L: Immunocytochemical distribution of bone small proteoglycans I and II in normal skin, hair follicle and pathological conditions: Evidence of aberrant protein core metabolism in pseudoxanthoma elasticum and the Hunter syndrome. Clin Res 38:929A, 1990. 48. McGowan T, Hegemann L, Webster GF, Lebwohl M, Sollberg S, Uitto J: Expression of protein kinase C-y in cultured cells derived from cutaneous neurofibroma. Clin Res 40:444A, 1992. 49. McGowan T, Hegemann L, Webster GF, Lebwohl M, Sollberg S, Uitto J: Expression of protein kinase C-y in cultured cells derived from cutaneous neurofibroma. J Invest Dermatol 98:584, 1992. 50. Keltz M, Lebwohl M, Bishop S: Peristomal pyoderma gangrenosum. Book of Abstracts, 18th World Congress of Dermatology 114A, 1992. 51. Lambroza E, Phelps R, Lebwohl M, Braverman I, Cohen SR: Hypopigmented mycosis fungoides. Book of Abstracts, 18th World Congress of Dermatology 129A, 1992. 61 52. Lebwohl M, Jacobs L, Schwartz E, Cruickshank F, Fleischmajer R, Sakai L, Feinberg E, Phelps R: Ultrastructural and immunofluorescent analysis of fibrillin in cutis laxa skin. Clin Res 40:478A, 1992. 53. Lebwohl M, Jacobs L, Schwartz E, Cruickshank F, Fleischmajer R, Sakai L, Feinberg E, Phelps R: Ultrastructural and immunofluorescent analysis of fibrillin in cutis laxa skin. J Invest Dermatol 98:617, 1992. 54. Lebwohl M, Schwartz E, Feinberg E, Phelps R: Effects of exogenous calcium and glycosaminoglycans on elastic tissue. Clin Res 41(2):403A, 1993. 55. Lebwohl M, Schwartz E, Feinberg E, Phelps R: Effects of exogenous calcium and glycosaminoglycans on elastic tissue. J Invest Dermatol 100:530, 1993. 56. Lebwohl M, Schwartz, Feinberg E, Phelps R: Effects of exogenous calcium and glycosaminoglycans on elastic tissue. Clin Res 41(2):506A, 1993. 57. Lebwohl M, Schwartz, Feinberg E, Phelps R: Effects of exogenous calcium and glycosaminoglycans on elastic tissue. J Invest Dermatol 100:514, 1993. 58. Lebwohl MG: Calcipotriene: US clinical experience. Calcipotriene Meeting Abstracts. Scottsdale, AZ, October 14-16, 1993. 59. Quell JM, Lebwohl M: A double-blind parallel study of the efficacy and safety of calcipotriene ointment 0.05% versus its vehicle in the treatment of plaque psoriasis. (DE127-001) Poster Abstracts. Washington, DC. 1993 Annual Meeting of the American Academy of Dermatology, December 4-9, 1993. 60. Lebwohl M, Medansky RS, Savin RC, Atton AV: A double-blind, multicenter study comparing the efficacy of diflorasone diacetate 0.05% cream in an optimized vehicle and fluocinonide 0.05% cream in the treatment of moderate to severe psoriasis. Poster Abstracts. Washington, DC. 1993 Annual Meeting of the American Academy of Dermatology, December 4-9, 1993. 61. Lebwohl M, Medansky RS, Savin RC, Atton AV: A double-blind multicenter study comparing the efficacy of diflorasone diacetate 0.05% cream in an optimized vehicle and fluocinonide 0.05% cream in the treatment of moderate to severe psoriasis. Poster Abstracts. Washington, DC. 1993 Annual Meeting of the American Academy of Dermatology, December 4-9, 1993. 62. Lebwohl M, Sapadin A, Argraves WS, Bruder J, Schwartz E: Synthesis of fibulin-I by dermal fibroblasts and its distribution in lesional pseudoxanthoma elasticum (PXE) and normal skins. J Invest Dermatol 102:574, 1994. 63. Sapadin A, Schwartz E, Lebwohl M: Fibrillin 5 synthesis in cultured pseudoxanthoma elasticum fibroblasts. J Invest Dermatol 102:575, 1994. 64. Schwartz E, Miller G, Lebwohl M, Kligman LH: Collagen gene expressions in ultraviolet irradiated hairless mice. J Invest Dermatol 102:603, 1994. 62 65. Lebwohl M: Vitamin D therapy. Proceedings of the VIth International Psoriasis Symposium, June23, 1994, Chicago, IL. 66. Lebwohl M: Problem psoriasis. Proceedings of the Gulf Council Conference League of Dermatology. 3rd International Conference. 67. Hecker D, Martinez J, Sapadin A, Patel B, Lebwohl M: Effect of topical calcipotriene on transmission of ultraviolet light on the stability of calcipotriene. J Invest Dermatol 104:659, 1995. 68 Lebwohl M: New topical therapies of psoriasis in A Therapeutic Update on Psoriasis – Symposium Proceedings, UCSF (Abstract) 69. Lebwohl MG, Medansky RS, Russo CL, Plott RT: A controlled, randomized study comparing the efficacy of sodium sulfacetamide 10%/sulfar 5% lotion and metronidazole 0.75% in the treatment of rosacea. (Poster Abstracts), 1996 Meeting of the American Academy of Dermatology. 70. Wang Y, Zhang X, Lebwohl M, Rosenstein B, Wei H: Inhibitory effect of a soybean isoflavone on ultraviolet B-induced protooncogene expression in sencar mouse skin. J Invest Dermatol 106:302, 1996. 71. Oang A, Wang Y, Lebwohl M, Rosenstein B, Wei H: Characterization of ultraviolet radiationinduced 8-ohydroxy-2’-deoxyguanosine formation in vitro: Role of wavelength and sensitization. J Invest Dermatol 106:303, 1996. 72. Wei H, Zhang A, Wang Y, Lebwohl M: Quenching of reactive oxygen species and ultraviolet radiation-induced oxidative DNA damage by soybean isoflavones. J Invest Dermatol 106:304, 1996. 73. Truter S, Sapadin A, Rosenbaum J, Schwartz E, MacDonald ED, Lebwohl M: Adult dermal fibroblasts produce the fetal protein fibrillin-2 in an in vitro skin model. J Invest Dermatol 106:532, 1996. 74. Truter S, Sapadin A, Rosenbaum J, Schwartz E, MacDonald ED, Lebwohl M: Role of fibrillin-2 in pseudoxanthoma elasticum. J Invest Dermatol 106:533, 1996. 75. Sapadin A, Schwartz E, Truter S, Rosenbaum J, Lebwohl M: Immunofluorescence analysis of the fibrillins in pseudoxanthoma elasticum (PXE) skin and in an in vitro three-dimensional culture model. J Invest Dermatol 106:552, 1996. 76. Sapadin A, Truter S, Rosenbaum J, MacDonald ED, Persaud A, Lebwohl M: Increased expression of type I collagen in cultured fibroblasts of white fibrous papulosis patients. J Invest Dermatol 106:553, 1996. 77. Sapadin A, Calderon P, Phelps R, Gordon M, Fleischmajer R, Lebwohl M: Toxic epidermal necrolysis induced by anticonvulsant/radiation therapy synergism. Program & Abstracts of the Fourteenth Annual Research Day, The Mount Sinai School of Medicine, p 34, 1996. 63 78. Sapadin A, Calderon P, Rudikoff D, Phelps R, Lebwohl M: Henoch-Schonlein purpura induced by Ciprofloxacin. Program & Abstracts of the Fourteenth Annual Research Day, The Mount Sinai School of Medicine, p 34, 1996. 79. Sapadin A, Bottone EJ, Phelps R, Gordon M, Lebwohl M: Disseminated cryptococcosis mimicking cutaneous necrotizing venulitis. Program & Abstracts of the Fourteenth Annual Research Day, The Mount Sinai School of Medicine, p 35, 1996. 80. Sapadin A, Kantor I, Phelps R, Schwartz IS, Lebwohl M: Lichen planus pemphigoides in the absence of clinically apparent bullae with a predominantly unilateral distribution. Program & Abstracts of the Fourteenth Annual Research Day, The Mount Sinai School of Medicine, p 36, 1996. 81. Sapadin A, Lebwohl M, Teich SA, DiCostanzo D, Phelps R, Cohen SR: Periumbilical pseudoxanthoma elasticum and angioid streaks associated with chronic renal failure. Program & Abstracts of the Fourteenth Annual Research Day, Mount Sinai School of Medicine, p 36, 1996. 82. Sapadin A, Schwartz E, Truter S, Rosenbaum J, Lebwohl M: Immunofluorescence analysis of the fibrillins in pseudoxanthoma elasticum (PXE) skin and in an in vitro three-dimensional culture model. Program & Abstracts of the Fourteenth Annual Research Day, The Mount Sinai School of Medicine, p 37, 1996. 83. Sapadin A, Schwartz E, Truter S, Rosenbaum J, MacDonald ED, Persaud A, Lebwohl M: Increased expression of type I collagen in cultured fibroblasts of white fibrous papulosis patients. Program & Abstracts of the Fourteenth Annual Research Day, The Mount Sinai School of Medicine, p 37, 1996. 84. Lebwohl M: A randomized, placebo-controlled trial of a norgestimate and ethinyl estradiol containing oral contraceptive in the treatment of acne vulgaris. Book of Abstracts of the 55th Annual Meeting of the American Academy of Dermatology, p 140, 1997. 85. Lebwohl M: Management of psoriasis with vitamin D used in combination with topical steroids. Abstracts of the First North American Calcipotriene/Calcipotriol Symposium, 1997. 86. Berman B, Lebwohl M, Lane AT, Mockoviak SH: Efficacy and safety of 0.1% mometasone furoate cream versus 0.2% hydrocortisone valerate cream in pediatric patients with atopic dermatitis unresponsive to topical hydrocortisone treatment. Book of Abstracts of the 55th Annual Meeting of the American Academy of Dermatology, p 143, 1997. 87. Sapadin AN, Lebwohl MG, Kantor I, Phelps RG: Lichen planus pemphigoides in the absence of clinically apparent bullae with a predominantly unilateral distribution. Book of Abstracts of the 55th Annual Meeting of the American Academy of Dermatology, p 146, 1997. 88. Sapadin AN, Lebwohl MG, Rudikoff D, Phelps RG: Henoch-Schonlein purpura induced by Ciprofloxacin. Book of Abstracts of the 55th Annual Meeting of the American Academy of Dermatology, p 146, 1997. 64 89. Sapadin AN, Gordon ML, Phelps RG, Lebwohl M: Toxic epidermal necrolysis induced by anticonvulsant/radiation therapy synergism. Book of Abstracts of the 55th Annual Meeting of the American Academy of Dermatology, p 146, 1997. 90. Sapadin AN, Cohen SR, Lebwohl MG, DiCostanzo D: Periumbilical pseudoxanthoma elasticum and angioid streaks associated with chronic renal failure. Book of Abstracts of the 55th Annual Meeting of the American Academy of Dermatology, p 149, 1997. 91. Sapadin AN, Lebwohl MG, Ravitz MS, Silvers DN: White fibrous papulosis: Report of an American series of six patients. Book of Abstracts of the 55th Annual Meeting of the American Academy of Dermatology, p 149, 1997. 92. Nichols K, Lebwohl MG: Effective sunscreen ingredients and cutaneous irritation in patients with rosacea. Book of Abstracts of the 55th Annual Meeting of the American Academy of Dermatology, p 149, 1997. 93. Lebwohl MG, Nichols K, Patel B, Siskin SB: Compatibility of various topical preparations with calcipotriene ointment. Book of Abstracts of the 55th Annual Meeting of the American Academy of Dermatology, p 151, 1997. 94. Lebwohl MG: Oral terbinafine in the treatment of toenail onychomycosis- pure nondermatophyte infection: A US multicenter clinical trial. Book of Abstracts of the 55th Annual Meeting of the American Academy of Dermatology, p 152, 1997. 95. Lebwohl MG, Zaias N: Efficacy and safety on terbinafine 1% solution in the treatment of interdigital-type tinea pedis and tinea corporis/cruris. Book of Abstracts of the 55th Annual Meeting of the American Academy of Dermatology, p 155, 1997. 96. Sapadin AN, Lebwohl MG, Gordon ML, Phelps RG. Disseminated cryptococcosis mimicking cutaneous necrotizing venulitis. Book of Abstracts of the 55th Annual Meeting of the American Academy of Dermatology, p 155, 1997. 97. Lebwohl M, Kang S, Guzzo, et al. CTLA41g (BMS-188667)-mediated blockade of T cell costimulation in patients with psoriasis vulgaris J Invest Dermatol 108:570, 1997. 98. Zhang X, Rosenstein BS, Wang Y, Lebwohl M, Wei H. Characterization of sensitizers and reactive oxygen species involved in ultraviolet-A radiation –induced oxidative DNA damage. J Invest Dermatol 108:600, 1997. 99. Sapadin A, Calderon P, Phelps R, Gordon M, Fleischmajer R, Lebwohl M: Toxic epidermal necrolysis induced by anticonvulsant/radiation therapy synergism. J Invest Dermal 108:614, 1997. 100. Sapadin A, Rahimizadeh A, Calderon P, Kemp M, Phelps RG, Lebwohl M: Histopathologic features of bullous pemphigoid in lichenoid lesions of patient with lichen planus pemphigoides. J Invest Dermatol 108:614, 1997. 65 101. Rosenstein B, Goldwyn S, Lebwohl M, Zhang X, Wei H: Differential expression of p53 and BCL-2 by UVA and UVB: A novel mechanism regulating UV-induced apoptosis. J Invest Dermatol 108:631, 1997. 102. Patel B, Siskin S, Krazmien R, Nichols K, Lebwohl M: Compatibility of various topical preparations with calcipotriene ointment. J Invest Dermatol 108:658, 1997. 103. Phelps R, Zhang X, Gelfand J, Wang Y, Lebwohl M: Protection of ultraviolet B radiation – induced photodamage in hairless mouse and human skin by isoflavone genistein. J Invest Dermatol 108:666, 1997. 104. Gelfand JM, Zhang X, Lebwohl M, Wei H: Photoprotective effect of the isoflavone genistein in a two stage photochemical carcinogenesis model. J Invest Dermatol 108:668, 1997. 105. Lebwohl M, Kang S. Guzzo C, Jegasothy B, Goldfarb M, Mann R, Goffe B, Menter A, Lowe N, Krueger G, Brown M, Weiner R, Birkhofer M, Warner G, Berry K, Linsley P, Krueger J, Ochs H, Kelley S, Abrams J; CTLA4Ig (BMS-188667)-mediated blockade of T cell costimulation in patients with psoriasis vulgaris. Abstracts of the 19th World Congress of Dermatology Austral J Dermatol 38(2):44, 1997. 106. Waldstreicher J, Thiboutot D, Dunlap F, Miller B, Winters P, Lebwohl M, Hecker D, Kraus S, Baldwin H, Shalita A, Draelos Z, Rapaport M, Markou M, Kang S, Kelly T, Pariser D, Leyden J, Webster G, Hordinsky M, Rietschel R, Katz I, Brumberger E, Best S: The effects of finasteride in men with frontal male pattern hair loss. Abstracts of the 19th World Congress of Dermatology. Austral J Dermatol 38(2):101, 1997. 107. Lebwohl M, Siskin S, McCreary H: Calcipotriene in combination with topical steroids for the treatment of psoriasis. Abstracts of the 19th World Congress of Dermatology. Austral J Dermatol 38(2):134, 1997. 108. Sapadin A, Rahimizadeh A, Phelps R, Lebwohl M: Identification of natural killer cells in the mononuclear infiltrates of lesions in the erythema multiforme spectrum of disease – An immunohistochemical study of twenty patients. Abstracts of the 19th World Congress of Dermatology. Austral J Dermatol 38(2):216, 1997. 109. Lebwohl M, Foged EK, Karvonen J, James IG, Grosshans E, van Heerden JS, Hall M, Hettler O: Terbinafine (1%) solution and emulsion gel: Two new formulations in one-week treatment of tinea pedis and tinea corporis/cruris. Abstracts of the 19th World Congress of Dermatology. Austral J Dermatol 38(2):273, 1997. 110. Lebwohl M: Safety of systemic therapies for psoriasis. Safety of Oral Dermatologic Agents Scientific from the 1997 Summer Session, American Academy of Dermatology pp8-9. 111. Lebwohl M: Use of calcipotriol in the treatment of psoriasis of the face and intertriginous areas, Book of Abstracts, Psoriasis Satellite Symposium, 6th Congress of The European Academy of Dermatology and Venereology. 66 112. Le Saux O, Urban Z, Csiszar K, Struk B, Terry S, Bercovitch L, Pope M, Lebwohl M, Uitto J, Lindpaintner K, Boyd CD: Pseudoxanthoma elasticum: A sib pair and haplotype analysis at 16p reveals a largely recessive disorder with variable penetrance in unrelated families from the United Kingdom and North America. Abstracts of the 1997 NIH Conference on Pseudoxanthoma Elasticum. 113. Sapadin AN, Teich S, Phelps RG, Cohen S, Lebwohl M: Periumbilical pseudoxanthoma elasticum – A case of hemodialysis-associated regression. Abstracts of the 1997 NIH Conference on Pseudoxanthoma Elasticum. 114. Wang Y, Rosenstein B, Goldwyn S, Lebwohl M, Zhang X, Wei H: Differential expression of P53 and BCL-2 by UVA and UVB: A novel mechanism regulating UV-induced apoptosis. Program and Abstracts, Fifteenth Annual Samuel Bronfman Department of Medicine Research Day, Mount Sinai School of Medicine, p 48, October 28, 1997. 115. Gelfand JM, Zhang X, Lebwohl M, Wei H: The isoflavone genistein inhibits ultraviolet B (UVB) induced initiation and promotion of otocarcinogenesis via an antioxidant mechanism. Program and Abstracts, Fifteenth Annual Samuel Bronfman Department of Medicine Research Day, Mount Sinai School of Medicine, p 48, October 28, 1997. 116. Nichols K, Dessai N, Lebwohl M: Effective sunscreen ingredients and cutaneous irritation in patients with rosacea. Program and Abstracts, Fifteenth Annual Samuel Bronfman Department of Medicine Research Day, The Mount Sinai School of Medicine, p 49, October 28, 1997. 117. Bercovitch L, Schepps B, Koellider S, Lebwohl M: Mammographic findings in pseudoxanthoma elasticum. Abstracts of the 1997 NIH Conference on PXE. 118. Lebwohl M: Clinically significant therapeutic interactions. Book of Abstracts of the American Dermatological Association, Inc., 117th Annual Meeting, p 33, 1997. 119. Wei H, Liu Z, Lu Y, Rosenstein B, Lebwohl M: Potentiating effect of benzo[a]pyrene on ultraviolet radiation –induced 8-hydroxy-2”- deoxyguanosine in purified DNA and human epidermoid carcinoma cells. J Invest Dermatol 110:526, 1998. 120. Mohl M, Urban Z, Elkwood A, Sandberg L, Mauch JC, Grand D, Goodwin S, Schwartz E, Lebwohl M, Schilling K, Green M, Girard M, Csiszar K, Boyd CD: Altered steady state levels of mRNAs encoding isoforms of tropoelastin are associated with actinic elastosis. J Invest Dermatol 110:599, 1998. 121. LeSaux O, Urban Z, Csiszar K, Struk, B, Terry S, Bercovitch L, Magro C, Pope M, Lebwohl M, Uitto J, Lindpaintner K, Boyd CD: Pseudoxanthoma elasticum: Confirmation of linkage to 16p13.1 and demonstration of a largely recessive inheritance in unrelated families from the United Kingdom and North America. J Invest Dermatol 110:614, 1998. 122. Gottlieb A, Krueger J, Bright R, Ling M, Lebwohl M, Kang S, Feldman S, Spellman M, Miller L, Ochs H, Dedrick R, Garovoy M: Phase I trial of psoriasis with an anti-CD11a (LFA-1) monoclonal antibody (mAb). J Invest Dermatol 110(4):679, 1998. 67 123. Le Saux O, Pope M, Urban Z, Csiszar K, Struk B, Terry S, Bercovitch L, Magro C, Lebwohl M, Uitto J, Lindpainter K, Boyd CD: Pseudoxanthoma elasticum: a sib pair and haplotype analysis at 16p reveals a largely dominant disorder with variable penetrance in unrelated families from the United Kingdom and North America. J Invest Dermatol 110:622, 1998. 124. Bercovitch D, Montemuino N, Bercovitch L, Terry S, Campbell J, Lebwohl M: Pregnancy and reproductive outcomes in pseudoxanthoma elasticum. J Invest Dermatol 110:591, 1998. 125. Lebwohl M, Hecker D: Acitretin in combination with UVB or PUVA. Book of Abstracts 5th European Congress on Psoriasis 7th International Psoriasis Forum, Milan, Italy, September 2-5, p 46, 1998. 126. Hecker D, Lebwohl M, Worsley J, Yueh G: Interaction between tazarotene and ultraviolet light. Book of Abstracts 5th European Congress on Psoriasis and 7th International Psoriasis Forum, Milan, Italy, September 2-5, p 155, 1998. 127. Yueh G, Hecker D, Lebwohl M, March D, Worsley J: Compatibility of tazarotene when compared with other topical treatment used for psoriasis. Book of Abstracts 5th European Congress on Psoriasis and 7th International Psoriasis Forum, Milan, Italy, September 2-5, p 156, 1998. 128. Tan M-H, Meador SL, Lebwohl MG: The safety and efficacy of limited application of fluticasone propionate ointment , 0.005%, in patients with atopic dermatitis of the face and intertriginous areas. 57th Annual Meeting of the American Academy of Dermatology, Poster Abstract Book, Abstract 89, March 1999. 129. Tan M-H, Lebwohl M: The penetration of fluticasone propionate ointment 0.005% in eyelid skin. 57th Annual Meeting of the American Academy of Dermatology, Poster Abstract Book, Abstract 223, March 1999. 130. Lebwohl M, Shupack J, Gottlieb A: Photographic documentation of the efficacy of cyclosporine in the treatment of severe plaque psoriasis. Poster Abstract Book, 57th Annual Meeting of the American Academy of Dermatology, March 1999. Hecker D, Lebwohl M, Worsley J, Yueh G: Interactions between tazarotene and ultraviolet light. Poster Abstract Book, 57th Annual Meeting of the American Academy of Dermatology, Abstract 232, March 1999. 131. 132. Yueh G, Hecker D, Lebwohl M, Marsh D, Worsley J: Compatibility of tazarotene when combined with other topical treatments used for psoriasis. Poster Abstract Book, 57th Annual Meeting of the American Academy of Dermatology, Abstract 233, March 1999. 133. Fiedler JA, Mauch J, Lebwohl M, Phelps R: Measuring elastin content: A new method for assessing topical steroid potency. Poster Abstract Book, 57th Annual Meeting of the American Academy of Dermatology, Abstract 234, March 1999. 68 134. Lawhorne MG, Lebwohl M, Phelps RG: The influence of the dermatologist in the education of patients with malignant melanoma. Poster Abstract Book, 57th Annual Meeting of the American Academy of Dermatology, Abstract 395, March 1999. 135. Tan M-H, Meador SL, Lebwohl MG: The safety and efficacy of limited application of fluticasone propionate ointment, 0.005%, in patients with psoriasis of the face and intertriginous areas. Poster Abstract Book, 57th Annual Meeting of the American Academy of Dermatology, Abstract 463, March 1999. 136. Lebwohl M, Shupack J, Gottlieb A: Photographic documentation of the efficacy of cyclosporine in the treatment of severe plaque psoriasis. Poster Abstract Book, 57th Annual Meeting of the American Academy of Dermatology, Abstract 464, March 1999. 137. Ahsan AA, Gottlieb AB, Sherr A, Shirin S, Solodnika G, Krueger J, Bright R, Ling M, Lebwohl M, Kang S, Feldman S, Spellman M, Garovoy M: Phase I trial of psoriasis with an anti-CD11A (LFA-1) monoclonal antibody (MAB). Poster Abstract Book, 57th Annual Meeting of the American Academy of Dermatology, Abstract 478, March 1999. 138. Celebi JT, Tsou HC, Chen FF, Zhang H, Ping XL, Lebwohl MG, Kezis J, Peacocke M: Phenotypic findings of Cowden syndrome and Bannayan-Zonana syndrome in a family associated with a single germline mutation in PTEN. J Med Genet 36(5):360-364 1999. 139. Koo K, Lebwohl M, Forney R: Severe atypical erythroderma precipitated by acute hepatitis B infection. J Invest Dermatol 112(4):603, 1999. 140. Wei H, Liu Z, Lu Y, Lebwohl M: PUVA (8-methoxy-psoralen plus ultraviolet A) induces for formation of 8-hydroxy-2’-deoxyguanosine and DNA fragmentation in calf thymus DNA and human epidermoid carcinoma cells. J Invest Dermatol 112(4):612, 1999. 141. Lebwohl M: Psoriasis treatment strategies and techniques to maximize efficacy, safety and remissions. Programs and Abstracts of the Summer Session of the 1999 American Academy of Dermatology. 142. Lebwohl M: An organized approach to the diagnosis of fever and rash. Abstract Book from the 5th GCC International Dermatology Congress, p 2, December 4-6, 1999. 143. Lebwohl M: New and emerging psoriasis therapies. Abstract Book from the 5th GCC International Dermatology Congress, p 2, December 4-6, 1999. 144. Lebwohl M, Tan M-H: The penetration of fluticasone propionate ointment 0.005% in eyelid skin. Book of Abstracts. Advances in Medical and Surgical Dermatology for the New Millennium. 145. Daly DJ, Li C, Lebwohl M, Phelps RG, Williams JD, Feldman S, Gropper C, Hoffman C: Diffuse scleroderma and metastatic EBV negative Schmincke’s type undifferentiated nasopharyngeal carcinoma, a case of collision or paraneoplasm. Book of Abstracts, 58th Annual Meeting of the American Academy of Dermatology, March 2000. 69 146. Koo K, Lebwohl M: Pyoderma gangrenosum: Diagnostic features and therapeutic responses. Book of Abstracts, 58th Annual Meeting of the American Academy of Dermatology, March 2000. 147. Lebwohl M: Short contact tazarotene therapy of psoriasis. Book of Abstracts. American Academy of Dermatology, Academy 2000, August 2-6, 2000. 148. Lebwohl M: An insider’s guide to new psoriasis treatments. Skin & Aging 44-48, June 2001. 149. Lebwohl M: Vitamin D and topical therapy. Abstracts, 2nd Joint Meeting International Psoriasis Symposium and European Congress, July 19-24, 2001. 150. Lebwohl M: Calcipotriene and UVB. Abstracts, 2nd Joint Meeting International Psoriasis Symposium and European Congress, July 19-24, 2001. 151. Lebwohl M: Systemic therapy and calcipotriene. Abstracts, 2nd Joint Meeting International Psoriasis Symposium and European Congress, July 19-24, 2001. 152. Lebwohl M: Vitamin D and scalp psoriasis. Abstracts, 2nd Joint Meeting International Psoriasis Symposium and European Congress, July 19-24, 2001. 153. Lebwohl M: Combination therapy: combinations of different topical agents and phototherapy. Abstracts, 2nd Joint Meeting International Psoriasis Symposium and European Congress, July 1924, 2001. 154. Lebwohl M: Combination therapy with systemic agents. Abstracts, 2nd Joint Meeting International Psoriasis Symposium and European Congress, July 19-24, 2001. 155. Lebwohl M: Topical vitamin D and recalcitrant scalp psoriasis. Abstracts, 2nd Joint Meeting International Psoriasis Symposium and European Congress, July 19-24, 2001. 156. Lebwohl M: Treatment of psoriasis in the new millennium: novel treatment approaches. Abstracts, 2nd Joint Meeting International Psoriasis Symposium and European Congress, July 19-24, 2001. 157. Lebwohl M: Clinical response to Alefacept, a genetically engineered human LFA3 and human IgG (LFA3TIP) fusion protein. Abstracts, 2nd Joint Meeting International Psoriasis Symposium and European Congress, July 19-24, 2001. 158. Lebwohl M: UVB and acitretin. Abstracts, 2nd Joint Meeting International Psoriasis Symposium and European Congress, July 19-24. 2001. 159. Lebwohl M: Strategies for psoriasis treatment, USA. Abstracts, 2nd Joint Meeting International Psoriasis Symposium and European Congress, July 19-24, 2001. 160. Lebwohl M, Scher R, Washenik K, Krueger G, Menter A, Koo J, Feldman SR: A randomized, double-blind, placebo-controlled study of the safety and efficacy of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis. Abstracts, 2nd Joint Meeting International Psoriasis 70 Symposium and European Congress, July 19-24, 2001. 161. Shyong E, Wei H, Lebwohl M, Austin L: A K17 peptide induces intracellular IFN-γ in lymphocytes from psoriasis vulgaris patients. J Invest Dermatol 117(2):324, 2001. 162. Shyong E, Lu Y, Phelps R, Lebwohl M, Wei H: Inhibition of PUVA-induced photodamage by the isoflavone genistein. J Invest Dermatol 117(2):674, 2001. 163. Ellis C, Drake L, Prendergast M, Abramovits W, Boguniewicz M, Daniel C, Lebwohl M, Stevens S, Whitaker-Worth D, Tong K. Third-party payer cost of atopic dermatitis and eczema in the United States. J Invest Dermatol 117(2):852, 2001. 164. Krupnick A, Clarke J, Fadness D, Singer G, Lebwohl M: Tacrolimus 0.1% ointment in the treatment of eyelid dermatitis. . J Invest Dermatol 117(2):861, 2001. 165. Persaud A, Shamuelova E, Sherer D, Lou W, Singer G, Cervera C, Lamba S, Lebwohl M: Imiquimod 5% cream is safe and effective in the treatment of actinic keratosis. . J Invest Dermatol 117(2):890, 2001. 166. Fuchs B, Franco J, Nelson J, Lebwohl M: Desonide 0.05%; excellent safety profile revealed by pharmacovigilance program. Book of Abstracts, American Academy of Dermatology, Academy 2002, February 22-27, 2002. 167. Gerstner GL, Suad A, Phelps R: The evaluation of TCA 20% vs a blue peel in the treatment of patients with skin types VI-VI. Book of Abstracts, American Academy of Dermatology, Academy 2002, February 22-27, 2002. 168. Krupnick AI, Linowski G, Lebwohl M: Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas. Book of Abstracts, American Academy of Dermatology, Academy 2002, February 22-27, 2002. 169. Shah AA, Galadari I, Lebwohl M: Medications that exacerbate psoriasis, Book of Abstracts, American Academy of Dermatology, Academy 2002, February 22-27, 2002. 170. Lebwohl M, Scher R, Washenik K, Krueger G: A randomized, double-blind, placebo-controlled study of the safety and efficacy of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis. Book of Abstracts, American Academy of Dermatology, Academy 2002, February 22-27, 2002. 171. Lebwohl M, Gottlieb A, Mease P, Burge D: Etanercept improves psoriasis activity in patients with psoriatic arthritis: Results of a Phase 3 multicenter clinical trial. Book of Abstracts, American Academy of Dermatology, Academy 2002, February 22-27, 2002. 172. Lebwohl M: Continued treatment with efalizumab (antiCD11a) improves outcome in patients with moderate to severe plaque psoriasis. Book of Abstracts, American Academy of Dermatology, Academy 2002, February 22-27, 2002. 71 173. Lebwohl M, Vigliani G, Krueger G: Results of a multiple-course, randomized Phase III study of alefacept (human FLA-3/IgG1) in patients with chronic plaque psoriasis. Book of Abstracts, American Academy of Dermatology, Academy 2002, February 22-27, 2002. 174. Eno C, Rizova E, Lebwohl M: Intramuscular administration of alefacept is safe and effective in patients with chronic plaque psoriasis: Results of an international randomized, double-blind, placebo-controlled, dose-comparison phase III study. Book of Abstracts, American Academy of Dermatology, Academy 2002, February 22-27, 2002. 175. Langley RD, Vigliani G, Lebwohl M: Study design and demographics of two phase III trials to evaluate weekly intravenous and intramuscular administration of alefacept in chronic plaque psoriasis. Book of Abstracts, American Academy of Dermatology, Academy 2002, February 2227, 2002. 176. Fazekas Z, Gao D, Lu Y, Saladi R, Austin LM, Lebwohl MG, Wei H: Chemopreventive potential of lycopene against photocarcinogenesis. Book of Abstracts, The Society for Investigative Dermatology, 63rd Annual Meeting, May 15-18, 2002, Los Angeles, CA. 177. Saladi RN, Austin LM, Lebwohl MG, Wei H: Immunohistochemical analysis of biomarkers for DNA adducts and DNA damage in carcinogenesis. Book of Abstracts, The Society for Investigative Dermatology, 63rd Annual Meeting, May 15-18, 2002, Los Angeles, CA. 178. Saladi RN, Austin LM, Gao D, Lu Y, Fazekas Z, Lebwohl MG, Wei H: Benzo[a]pyrene plus Ultraviolet A exposures cause a time-related accumulation of DNA damage. Book of Abstracts, The Society for Investigative Dermatology, 63rd Annual Meeting, May 15-18, 2002, Los Angeles, CA. 179. Austin LM, Saladi RN, Gao D, Lebwohl MG, Wei H: Chronic exposure to benzo[a]pyrene plus UVA induces redistribution of dendritic cells within the skin of tumor-prone SKH-1 mice. Book of Abstracts, The Society for Investigative Dermatology, 63rd Annual Meeting, May 15-18, 2002, Los Angeles, CA. 180. Bartsch M, Taneja R, Lu Y, Lebwohl MG, Wei H, Austin LM: Expression of Stra13, a retinoic acid-induced transcription factor, in SVK-14 human keratinocytes. Book of Abstracts, The Society for Investigative Dermatology, 63rd Annual Meeting, May 15-18, 2002, Los Angeles, CA. 181. Singh F, Gao D, Lebwohl M, Wei H: A natural novel compound Shikonin the mechanism of its anticancer action on ultraviolet-B induced skin carcinogenesis. Book of Abstracts, The Society for Investigative Dermatology, 63rd Annual Meeting, May 15-18, 2002, Los Angeles, CA. 182. Freeman AK, Singer S, Linowski G, Lebwohl M. Tacrolimus ointment for the maintenance of atopic dermatitis. Poster Abstract Book, 61st Annual Meeting of the American Academy of Dermatology, Poster 208, March 2003. 72 183. Foley V, Breneman D, Kraus S, Lebwohl M. Clobetasol propionate 0.05% is equivalent as lotion or emollient cream in atopic dermatitis. Poster Abstracts Book, 61st Annual Meeting of the American Academy of Dermatology, Poster 221, March 2003. 184. Lebwohl M. A multicenter, randomized, double-blind, vehicle-controlled study of the efficacy and safety of 1% ciclopirox shampoo in the treatment of seborrheic dermatitis of the scalp. Poster Abstracts Book, 61st Annual Meeting of the American Academy of Dermatology, Poster 392, March 2003. 185. Gerstner G, Lebwohl M, Gordon M, Phelps R. The role of digital body mapping in the clinical setting. Poster Abstracts Book, 61st Annual Meeting of the American Academy of Dermatology, Poster 499, March 2003. 186. Carrasco DA, Hadi SM, Spencer J, Lebwohl M. The use of 308-nm excimer laser for the treatment of vitiligo. Poster Abstracts Book, 61st Annual Meeting of the American Academy of Dermatology, Poster 567, March 2003. 187. Gordon KB, Trying S, Hamilton T, Lebwohl M. Examining duration of response and relapse during treatment with efalizumab. Poster Abstracts Book, 61st Annual Meeting of the American Academy of Dermatology, Poster 594, March 2003. 188. Koo J, Menter A, Lebwohl M, Kozma C. The relationship between quality of life and disease severity: Results from a large cohort of mild, moderate, and severe psoriasis patients. Poster Abstracts Book, 61st Annual Meeting of the American Academy of Dermatology, Poster 605, March 2003. 189. Koo J, Kozma C, Menter A, Lebwohl M. Development of the 12 item psoriasis Quality of Life questionnaire (PQOL). Poster Abstracts Book, 61st Annual Meeting of the American Academy of Dermatology, Poster 606, March 2003. 190. Lebwohl M, Bos JD, Vaishnaw A, Lynn F. Variability in circulating T-cell subsets among placebo-treated patients with psoriasis. Poster Abstracts Book, 61st Annual Meeting of the American Academy of Dermatology, Poster 609, March 2003. 191. Menter A, McCune M, Lynde C, Lebwohl M. Effects of efalizumab (Anti-CD11a) on pruritus in subjects with moderate to severe plaque psoriasis. Poster Abstracts Book, 61st Annual Meeting of the American Academy of Dermatology, Poster 612, March 2003. 192. Luo Y, Guevara D, Saladi RN, Rui M Goldwyn B, Lebwohl M, Gao D, Wei H . Benzo[a]pyrene metabolites enhance the formation of reactive oxygen species and DNA oxidative damage in UVA-irradiated calf-thymus DNA (Poster). The 4th Joint Meeting of the European Society for Dermatological Research, Japanese Society for Investigative Dermatology, Society for Investigative Dermatology April 30-May 4, 2003. 193. Palep SR, Saladi RN, Moore J, Lebwohl M, Wei H. Expression of proliferating cell nuclear antigen in mouse skin at different time points following ultraviolet B exposure. (Poster). The 4th Joint Meeting of the European Society for Dermatological Research, Japanese Society for Investigative Dermatology, Society for Investigative Dermatology April 30-May 4, 2003. 73 194. Fazekas Z, Gao D, Saladi RN, Lu Y, Lebwohl M, Wei H. Immuno-histochemical evaluation of lycopene’s protective effect against ultraviolet B (UVB)-induced photodamage in vivo. (Poster). The 4th Joint Meeting of the European Society for Dermatological Research, Japanese Society for Investigative Dermatology, Society for Investigative Dermatology April 30-May 4, 2003. 195. Saladi RN, Perez E, Gao D, Palep S, Luo Y, Lu Y, Phelps RG, Lebwohl M, Wei H. The synergistic carcinogenic effects of benzo(a)pyrene with ultraviolet radiation: models & mechanisms. (Poster) The 4th Joint Meeting of the European Society for Dermatological Research, Japanese Society for Investigative Dermatology, Society for Investigative Dermatology April 30-May 4, 2003. 196. Moore JO, Gao D, Saladi RN, Maryles S, Palep S, Lebwohl M, Wei H. Shikonin inhibits proliferation of human melanoma cell lines. (Poster) The 4th Joint Meeting of the European Society for Dermatological Research, Japanese Society for Investigative Dermatology, Society for Investigative Dermatology April 30-May 4, 2003. 197. Lebwohl M, Blum R, Kim D, Do T, Wallis W, Rubin A, Burge D, Zitnik R. Cutaneous squamous cell carcinoma incidence is not increased in rhematoid arthritis patients receiving etanercept. (Poster) The 4th Joint Meeting of the European Society for Dermatological Research, Japanese Society for Investigative Dermatology, Society for Investigative Dermatology April 30May 4, 2003. 198. Lebwohl M, Sanda M, Wajdula J, Zitnik R, Burge D, Wallis WJ. Global safety and efficacy of more than 5 years of etanercept (ENBREL®) therapy in rheumatoid arthritis. The 4th Joint Meeting of the European Society for Dermatological Research, Japanese Society for Investigative Dermatology, Society for Investigative Dermatology April 30-May 4, 2003. 199. Lebwohl M. Rationale for the Use of Efalizumab in Psoriasis. The 9th International Psoriais Symposium June 17-22, 2003, New York, NY. 200. Lebwohl M. T-Cell Targeting with Biologics: A New Approach to Treating Psoriasis. The 9th International Psoriais Symposium June 17-22, 2003, New York, NY. 201. Spuls P, Lebwohl M. Treatment of Nail Psoriasis. The 9th International Psoriais Symposium June 17-22, 2003, New York, NY. 202. Lebwohl M, Walicke P, Wang X, Compton P, Kaplowitz H, Curkendall S, Goehring E. No Evidence for Increased Risk of Infection during Efalizumab Treatment. The 9th International Psoriais Symposium June 17-22, 2003, New York, NY. 203. Lebwohl M, Berkowitz E, Blum R, Kim D, Do T, Wallis WJ, Rubin A, Zitnik R. Cutaneous Squamous Cell Carcinoma Incidence Is Not Increased in Rheumatoid Arthritis Patiens Receiving Enbrel ® (Etanercept) The 9th International Psoriais Symposium June 17-22, 2003, New York, NY. 74 204. Sapadin IR, Lamba S, Phelps R, Lebwohl M. Sweet’s-Like Vasculities Induced by Granulocyte Colony-Stimulating Factor Therapy in a Patient with Bladder Carcinoma. 62nd Annual Meeting American Academy of Dermatology February 6-11, 2004, Washington, DC. 205. Goffe BS, Gottlieb A, Lebwohl M, Zitnik R. Etanercept in Patients with Psoriatic Arthritis Sustained Improvement in Skin and Joint Disease. J Am Acad Dermatol. 50(3): Suppl 1, 2004, p P55. 206. Jorizzo J, Lebwohl M, Salasche S, Stockfleth E. Different Dosing Regimens of Imiquimod 5% Cream Can Be Used to Safely and Effectively Treat Actinic Keratosis. 62nd Annual Meeting American Academy of Dermatology February 6-11, 2004, Washington, DC. 207. Carrasco DA, Lebwohl M, Tannis C. Acitretin Suppression of Squamous Cell Carcinoma. 62nd Annual Meeting American Academy of Dermatology February 6-11, 2004, Washington, DC. 208. Krueger GG, Lebwohl M, Wang A, Zitnek R. Continuance on Etanercept After Early Incomplete Response in Patients With Psoriasis. J Am Acad Dermatol. 50(3): Suppl 1, 2004, p P141. 209. Blum RR, Stern D, Koo J, Lebwohl M. a Multi-Center Study of Calcipotriene 0.005% Ointment and Clobertasol Proprionate 0.05% Foam in the Sequential Treatment of Localized Plaque-type Psoriasis. 62nd Annual Meeting American Academy of Dermatology February 6-11, 2004, Washington, DC. 210. Gribetz CH, Blum R, Cohen S, Lebwohl M. A 12-Week Open-Label Followed By 4-Week Double-Blind Study to Determine the Safety and Efficacy of an Extended Course of Alefacrpt (LFA-3IGGI Fusion Protein) in Subjects with Chronic Plaque Psoriasis. 62nd Annual Meeting American Academy of Dermatology February 6-11, 2004, Washington, DC. 211. Lebwohl M, Gottlieb A, Wallis W. Zitnek R. Global Safety and Efficacy of More Than 5 Years of Etanercept Therapy in Rheumatoid Arthritis. J Am Acad Dermatol. 50(3): Suppl 1, 2004, p P142. 212. Stebbins WG, Saladi RN, Moore JO, Phelps RG, Lebwohl MG, Wei H. Correlation of hypoxia inducible factor-Iα expression with worsening grades of squamous dysplasia. J Invest Dermatol. 122(3): A22, 2004. 213. Moore JO, Palep SR, Saladi RN, Gao D, Wang Y, Phelps R, Lebwohl MG, Wei H. Effects of ultraviolet B exposure on the expression of proliferating cell nuclear antigen (PCNA) in murine skin. J Invest Dermatol. 122(3): A23, 2004. 214. Moore JO, Stebbins WG, Guevara D, Saladi RN, Zhu Y, Lebwohl MG, Wei H. Human skin equivalent: a reliable in vitro model for carcinogenic experiments. J Invest Dermatol. 122(3): A23, 2004. 215. Palep SR, Guevara D, Moore JO, Saladi RN, Gao D, Lebwohl MG, Wei H. The effects of chemopreventive agents on DNA damage and PCNA expression on mouse skin treated with BaP-UVA. J Invest Dermatol. 122(3): A24, 2004. 75 216. Saladi RN, Wang Y, Phelps RG, Lebwohl MG, Wei H.Hypoxia-inducible factor 1α (HIF-1α) involves inactivation of transcription responses to tumor growth as well as cellular apoptosis. J Invest Dermatol. 122(3): A25, 2004. 217. Guevara D, Chi W, Gao D, Zhou X, Wang Y, Zhu Y, Lebwohl M, Wei H. UVA modifies UVBinduced skin carcinogenesis in vivo. J Invest Dermatol. 122(3): A26, 2004. 218. Wang Y, Gao D, Saladi R, Moore J, Lebwohl M, Wei H. Early occurrence of H-ras gene mutations by synergistic benzo[a]pyrene and UVA at sub-carcinogenic levels in the skin of SKH-1 mice. . J Invest Dermatol. 122(3): A28, 2004. 219. Ringpfeil F, McGuigan K, Fuchsel L, Kozic H, Lebwohl M, Uitto J. Autosomal dominant inheritance in pseudoxanthoma elasticum revisited. . J Invest Dermatol. 122(3): A92, 2004. 220. Gao D, Guevara D, Zhou X, Wang Y, Zhu Y, Lebwohl M, Wei H. Combination of benzo[a]pyrene and ultraviolet A promotes tumor propagation. . J Invest Dermatol. 122(3): A127, 2004. 221. Lebwohl M, Gottlieb A, Goffe BS, Jahreis A. Etanercept in Psoriatic Arthritis: Sustained Improvement in Skin and Joint Disease and Inhibition of Radiographic Progression at 2 Years. J Am Acad Dermatol.2005; 52: pAB8. 222. Lebwohl M, Gottlieb A, Goffe BS, Jahreis A. Etanercept in Psoriatic Arthritis: Sustained Improvement in Skin and Joint Disease and Inhibition of Radiographic Progression at 2 Years. J Am Acad Dermatol 52: p184, 2005. 223. Menter A, Baker D, Farber H, Lebwohl M. Long-term Use of Alefacept Efficacy and Offtreatment Responses in Patients Who Have Received Multiple Courses of Therapy. J Am Acad Dermatol 52: p2, 2005. 224. Zeicher J, Lebwohl M. Pilot Investigation of Topical Tacrolimus 0.1% Gel in Combination with Topical Hydrocortisone Butyrate 0.1% Lipocream in the Treatment of Atopic Dermatitis. J Am Acad Dermatol 52: p72, 2005. 225. Blum R, Stern D, Lebwohl M, Koo J. A Multicenter Study of Calcipotriene Ointment 0.005% and Clobetasol Propionate Foam 0.05% in the Sequential treatment of Localized Plaque-type Psoriasis. J Am Acad Dermatol 52: p172, 2005. 226. Lebwohl M, Gottlieb A, Wallis W, Zitnik R. Safety and Efficacy of Over 7 Years of Etanercept Therapy in a Global Population of Patients with Rheumatoid Arthritis. J Am Acad Dermatol 52: p195, 2005. 227. Langley RG, Lebwohl M, Leonardi C, Yeilding N, Guzzo C, Wang Y, Dooley L, Krueger GG. Phase II Study of a Human anti-Interleukin (IL)-12/IL-23 Monoclonal Antibody in the Treatment of Psoriasis. . J Invest Dermatol 407: pA69, 2005. 76 228. Fazekas Z, Kantor I, Lebwohl M. A Patient with Pityriasis Rubra Pilaris Responds to Therapy with Alefacept. 64th Annual Meeting American Academy of Dermatology March 3-7, 2006, San Francisco, CA. J AmerAcad Dermatol, Abstract in Press. 229. Zeichner J, Lebwohl M. Long-Term, Low-Dose Acitretin Therapy for Psoriasis Does Not Cause Significant Skeletal Side Effects. 64th Annual Meeting American Academy of Dermatology March 3-7, 2006, San Francisco, CA. J Amer Acad Dermatol, (Abstract in Press) 230. Gribetz C, Lebwohl M. Maintenance of Response in Patients with Chronic Plaque Psoriasis Following an Extended 16-Week Course of Alefacept. 64th Annual Meeting American Academy of Dermatology March 3-7, 2006, San Francisco, CA. J Amer Acad Dermatol, Abstract in Press 231. Lebwohl M. Etanercept Therapy Maintains High PASI Responses in Psoriasis Patients Independent of Reported Psoriatic Arthritis. 64th Annual Meeting American Academy of Dermatology March 3-7, 2006, San Francisco, CA. J Amer Acad Dermatol, Abstract in Press 232. Trokhan E, Wei H, Lebwohl M. Pilot Study of the Effects of a 1% Genistein Ointment in PUVATreated Psoriasis Patients. 64th Annual Meeting American Academy of Dermatology March 3-7, 2006, San Francisco, CA. J Amer Acad Dermatol, Abstract in Press 233. Blum R, Phelps R, Fuchs W, Lebwohl M. Oral Phosphate Binders in the Treatment of Pseudoxanthoma Elasticum. 64th Annual Meeting American Academy of Dermatology March 37, 2006, San Francisco, CA. J Amer Acad Dermatol, Abstract in Press 234. Lebwohl M.Pooled, Comparative Analysis of One-Two- and Four-Week Efficacy Rates of Calcipotriene/Betamethasone in Severe Psoriasis. 64th Annual Meeting American Academy of Dermatology March 3-7, 2006, San Francisco, CA. J Amer Acad Dermatol, Abstract in Press 235. Zeichner J, Lebwohl M. Intralesional Etanercept for the Treatment of Necrobiosis Lipoidica. 64th Annual Meeting American Academy of Dermatology March 3-7, 2006, San Francisco, CA. J Amer Acad Dermatol, Abstract in Press 236. Menter A, Lebwohl M. Efficacy and Safety of Up to Three Courses of Intramuscular Alefacept. 64th Annual Meeting American Academy of Dermatology March 3-7, 2006, San Francisco, CA. J Amer Acad Dermatol, Abstract in Press 237. Krueger GG, Langley R, Leonardi C, Lebwohl M. Results of a Phase II Study of CNTO 1275 in the Treatment of Psoriasis. 64th Annual Meeting American Academy of Dermatology March 3-7, 2006, San Francisco, CA. J Amer Acad Dermatol, Abstract in Press 238. Lebwohl M. Pooled, comparative analysis of one , 2- and 4-week efficacy rates of the twocompound product calcipotriol/betamethasone dipropionate in severe psoriasis. J Invest Dermatol 2007;127:1817. 239. Krueger GG, Langley R, Lebwohl M. Results of a Phase II Study of CNTO 1,275 in the Treatment of Psoriasis. J Invest Dermatol 2007;127:1817. Updated: 05.19.11
